Q2 false false True false 0000730272 false--12-31 0000730272 us-gaap:RetainedEarningsMember rgen:OtherAdjustmentsMember 2023-12-31 0000730272 us-gaap:PatentsMember 2023-12-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:RestatementAdjustmentMember 2024-06-30 0000730272 us-gaap:PrincipalOwnerMember 2023-01-01 2023-06-30 0000730272 rgen:FlexbiosysIncMember 2023-01-01 2023-06-30 0000730272 2023-03-31 0000730272 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2024-01-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:RestatementAdjustmentMember 2024-03-31 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-04-01 2023-06-30 0000730272 srt:RestatementAdjustmentMember 2023-12-31 0000730272 rgen:FlexbiosysIncMember us-gaap:NoncompeteAgreementsMember 2024-01-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ExchangedTwoZeroOneNineNotesMember 2023-01-01 2023-12-31 0000730272 rgen:FacilityAndOtherExitCostsMember us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0000730272 2023-01-01 2023-06-30 0000730272 rgen:AcceleratedDepreciationMember 2024-04-01 2024-06-30 0000730272 rgen:NotesMember 2023-12-14 0000730272 rgen:FlexbiosysIncMember us-gaap:NoncompeteAgreementsMember 2024-06-30 0000730272 us-gaap:CommonStockMember rgen:FlexbiosysIncMember 2023-01-01 2023-06-30 0000730272 2024-06-30 0000730272 2024-06-13 0000730272 rgen:AcceleratedDepreciationMember us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember 2024-04-01 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0000730272 rgen:MonteCarloSimulationMember srt:MinimumMember rgen:RevenueAndVolumeBasedPaymentsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0000730272 us-gaap:CommonStockMember rgen:FlexbiosysIncMember 2023-04-01 2023-06-30 0000730272 us-gaap:RoyaltyMember 2023-01-01 2023-06-30 0000730272 us-gaap:RetainedEarningsMember 2022-12-31 0000730272 srt:RestatementAdjustmentMember us-gaap:RoyaltyMember 2024-04-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember us-gaap:CommonStockMember 2024-06-30 0000730272 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0000730272 us-gaap:CommonStockMember 2023-06-30 0000730272 rgen:NGLImpactAMember us-gaap:ResearchAndDevelopmentArrangementMember 2023-04-01 2023-06-30 0000730272 rgen:MetenovaHoldingAbMember 2024-01-01 2024-06-30 0000730272 rgen:TwoThousandTwentyFourAwardAmendmentMember 2024-01-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2024-04-01 2024-06-30 0000730272 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ExchangeAndSubscriptionAgreementsMember 2023-12-14 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember srt:ExecutiveOfficerMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2024-01-01 2024-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:CustomerRelationshipsMember 2024-01-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember 2023-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember rgen:OtherAdjustmentsMember 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember 2024-06-30 0000730272 us-gaap:RoyaltyMember rgen:OtherAdjustmentsMember 2024-01-01 2024-06-30 0000730272 us-gaap:RoyaltyMember 2023-04-01 2023-06-30 0000730272 rgen:NGLImpactAMember us-gaap:ResearchAndDevelopmentArrangementMember 2024-04-01 2024-06-30 0000730272 rgen:AcceleratedDepreciationMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0000730272 rgen:MonteCarloSimulationMember rgen:ManufacturingLineExpansionsMember us-gaap:FairValueMeasurementsRecurringMember rgen:ContingentConsiderationMember 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-06-30 0000730272 rgen:AcceleratedDepreciationMember 2024-01-01 2024-06-30 0000730272 us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0000730272 rgen:TwoZeroTwoNineteenNotesMember 2023-06-30 0000730272 us-gaap:BuildingMember 2024-06-30 0000730272 rgen:MonteCarloSimulationMember srt:MinimumMember rgen:AvitideFlexbiosysAndMetenovaMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000730272 us-gaap:SalesRevenueNetMember srt:MinimumMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0000730272 rgen:TwoZeroTwoNineteenNotesMember 2024-04-01 2024-06-30 0000730272 rgen:OtherAdjustmentsMember 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember 2024-04-01 2024-06-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0000730272 rgen:OtherAdjustmentsMember 2023-12-31 0000730272 us-gaap:SalesRevenueNetMember srt:MinimumMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0000730272 us-gaap:SalesRevenueNetMember srt:NorthAmericaMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-06-30 0000730272 rgen:TwoThousandTwentyFourGrantsMember 2024-04-01 2024-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2024-01-01 2024-06-30 0000730272 rgen:PerformanceStockUnitsMember rgen:TwoThousandTwentyFourAwardAmendmentMember 2024-01-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:RestatementAdjustmentMember 2023-12-31 0000730272 rgen:TrademarkMember 2023-12-31 0000730272 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000730272 rgen:FacilityAndOtherExitCostsMember us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000730272 rgen:OtherAdjustmentsMember 2024-04-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2024-06-30 0000730272 us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:SubscriptionTransactionsMember 2023-12-14 0000730272 rgen:ContingentConsiderationMember 2024-06-30 0000730272 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2024-04-01 2024-06-30 0000730272 rgen:MonteCarloSimulationMember rgen:RevenueAndVolumeBasedPaymentsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000730272 rgen:StockOptionAndIncentivePlanMember 2024-06-30 0000730272 2024-01-01 2024-06-30 0000730272 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000730272 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000730272 rgen:AvitideIncMember 2024-01-01 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember 2023-01-01 2023-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000730272 rgen:UnvestedOptionsMember 2024-01-01 2024-06-30 0000730272 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000730272 us-gaap:RetainedEarningsMember rgen:OtherAdjustmentsMember 2024-04-01 2024-06-30 0000730272 rgen:CustomerNumberOneMember us-gaap:CustomerConcentrationRiskMember rgen:TotalTradeAccountsReceivableRoyaltiesAndOtherReceivablesMember 2024-01-01 2024-06-30 0000730272 us-gaap:RoyaltyMember rgen:OtherAdjustmentsMember 2024-04-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000730272 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0000730272 rgen:TwoZeroTwoNineteenNotesMember 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember 2024-04-01 2024-06-30 0000730272 rgen:ManufacturingLineExpansionsMember rgen:ProbabilityWeightedPresentValueMember us-gaap:FairValueMeasurementsRecurringMember rgen:ContingentConsiderationMember rgen:MeasurementInputEarnoutDiscountRateMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2023-12-31 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-04-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember 2024-04-01 2024-06-30 0000730272 rgen:MetenovaHoldingAbMember 2024-04-01 2024-06-30 0000730272 srt:ScenarioForecastMember 2024-06-13 2024-09-01 0000730272 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2023-12-31 0000730272 srt:RestatementAdjustmentMember 2024-01-01 2024-06-30 0000730272 srt:RestatementAdjustmentMember 2024-03-31 0000730272 us-gaap:RetainedEarningsMember 2023-03-31 0000730272 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000730272 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000730272 us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2024-04-01 2024-06-30 0000730272 us-gaap:ProductMember rgen:OtherAdjustmentsMember 2024-04-01 2024-06-30 0000730272 us-gaap:ProductMember rgen:OtherAdjustmentsMember 2024-01-01 2024-06-30 0000730272 us-gaap:CustomerRelationshipsMember 2024-06-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0000730272 rgen:StockOptionAndIncentivePlanMember 2018-12-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember 2023-12-06 0000730272 rgen:TwoZeroTwoNineteenNotesMember 2023-01-01 2023-06-30 0000730272 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember rgen:OtherAdjustmentsMember 2024-03-31 0000730272 rgen:FlexbiosysIncMember us-gaap:DevelopedTechnologyRightsMember 2024-01-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000730272 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-06-30 0000730272 rgen:TwoZeroTwoNineteenNotesMember 2024-01-01 2024-06-30 0000730272 us-gaap:TrademarksMember 2024-06-30 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-06-30 0000730272 us-gaap:CommonStockMember 2023-03-31 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember 2024-06-30 0000730272 rgen:FlexbiosysIncMember 2024-03-31 0000730272 srt:ScenarioPreviouslyReportedMember us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0000730272 rgen:AcceleratedDepreciationMember 2023-12-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:RestatementAdjustmentMember 2024-04-01 2024-06-30 0000730272 2023-04-01 2023-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:TwoZeroTwoThreeNotesMember 2024-04-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000730272 rgen:TwoThousandTwentyFourGrantsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ExchangeTransactionMember 2023-12-14 2023-12-14 0000730272 srt:RestatementAdjustmentMember 2024-04-01 2024-06-30 0000730272 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:TradeNamesMember 2024-01-01 2024-06-30 0000730272 us-gaap:TrademarksMember 2023-12-31 0000730272 rgen:MetenovaHoldingAbMember us-gaap:TradeNamesMember 2024-01-01 2024-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000730272 us-gaap:PrincipalOwnerMember 2024-01-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:FairValueOfEmbeddedConversionOptionMember rgen:ModifiedTwoZeroOneNineNotesMember 2023-01-01 2023-12-31 0000730272 rgen:NGLImpactAMember us-gaap:ResearchAndDevelopmentArrangementMember 2023-01-01 2023-06-30 0000730272 rgen:AcceleratedDepreciationMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:NoncompeteAgreementsMember 2024-01-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000730272 rgen:FlexbiosysIncMember 2023-04-01 2023-06-30 0000730272 us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2024-01-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2024-03-31 0000730272 rgen:MonteCarloSimulationMember rgen:AvitideFlexbiosysAndMetenovaMember us-gaap:FairValueMeasurementsRecurringMember rgen:ContingentConsiderationMember rgen:MeasurementInputEarnoutDiscountRateMember 2024-06-30 0000730272 us-gaap:RestrictedStockUnitsRSUMember 2024-06-28 0000730272 rgen:FacilityAndOtherExitCostsMember 2024-01-01 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000730272 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2024-03-31 0000730272 rgen:MetenovaHoldingAbMember 2023-10-02 0000730272 2023-12-31 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember 2024-01-01 2024-06-30 0000730272 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember us-gaap:PrivatePlacementMember 2023-12-14 0000730272 rgen:MonteCarloSimulationMember rgen:AvitideFlexbiosysAndMetenovaMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000730272 us-gaap:ProductMember 2023-04-01 2023-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember rgen:OtherAdjustmentsMember 2024-01-01 2024-06-30 0000730272 srt:ScenarioPreviouslyReportedMember 2024-03-31 0000730272 us-gaap:CommonStockMember rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-19 0000730272 rgen:MetenovaHoldingAbMember 2023-10-02 2023-10-02 0000730272 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember 2023-04-01 2023-06-30 0000730272 rgen:AcceleratedDepreciationMember us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000730272 us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2024-01-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ScenarioPreviouslyReportedMember 2024-03-31 0000730272 2024-07-26 0000730272 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000730272 rgen:FlexbiosysIncMember us-gaap:TradeNamesMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2023-12-14 0000730272 srt:RestatementAdjustmentMember 2024-06-30 0000730272 rgen:NGLImpactAMember us-gaap:ResearchAndDevelopmentArrangementMember 2024-01-01 2024-06-30 0000730272 us-gaap:RestrictedStockUnitsRSUMember rgen:TwoThousandTwentyFourAwardAmendmentMember 2024-01-01 2024-06-30 0000730272 us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000730272 rgen:AcceleratedDepreciationMember 2024-06-30 0000730272 us-gaap:CommonStockMember 2024-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:CommonStockMember 2023-04-17 2023-04-17 0000730272 rgen:TwoZeroTwoThreeNotesMember 2024-04-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ModifiedTwoZeroOneNineNotesMember 2023-12-31 0000730272 rgen:ContingentConsiderationMember 2024-01-01 2024-06-30 0000730272 rgen:MonteCarloSimulationMember rgen:AvitideFlexbiosysAndMetenovaMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember rgen:MeasurementInputProbabilityOfSuccessMember 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember srt:NorthAmericaMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember us-gaap:SubsequentEventMember 2024-07-15 2024-07-15 0000730272 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:TwoZeroTwoThreeNotesMember 2023-12-31 0000730272 us-gaap:RoyaltyMember srt:ScenarioPreviouslyReportedMember 2024-04-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ExchangedTwoZeroOneNineNotesMember 2023-12-14 2023-12-14 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:SubscriptionTransactionsMember 2023-12-14 2023-12-14 0000730272 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000730272 rgen:MonteCarloSimulationMember rgen:AvitideFlexbiosysAndMetenovaMember us-gaap:FairValueMeasurementsRecurringMember rgen:ContingentConsiderationMember srt:MaximumMember 2024-06-30 0000730272 us-gaap:CommonStockMember rgen:MetenovaHoldingAbMember 2023-10-02 2023-10-02 0000730272 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000730272 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ExchangedTwoZeroOneNineNotesMember 2023-12-31 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:NorthAmericaMember 2024-04-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:RestatementAdjustmentMember 2024-01-01 2024-06-30 0000730272 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000730272 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:SubscriptionTransactionMember 2023-12-14 0000730272 rgen:CustomerNumberOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000730272 us-gaap:CommonStockMember 2022-12-31 0000730272 us-gaap:CommonStockMember 2023-12-31 0000730272 2022-12-31 0000730272 rgen:ExchangeTransactionMember rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2023-12-31 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000730272 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ScenarioPreviouslyReportedMember 2023-12-31 0000730272 us-gaap:RetainedEarningsMember 2024-06-30 0000730272 us-gaap:EmployeeStockOptionMember srt:ExecutiveOfficerMember 2024-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000730272 rgen:NovoNordiskASMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember rgen:NonExecutiveMember 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:TwoZeroTwoThreeNotesMember 2024-06-30 0000730272 us-gaap:CustomerRelationshipsMember 2023-12-31 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ModifiedTwoZeroOneNineNotesMember us-gaap:AdditionalPaidInCapitalMember 2023-12-14 2023-12-14 0000730272 us-gaap:RetainedEarningsMember 2023-12-31 0000730272 rgen:MonteCarloSimulationMember rgen:RevenueAndVolumeBasedPaymentsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember srt:MaximumMember 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember 2023-12-14 0000730272 rgen:TrademarkMember 2024-06-30 0000730272 rgen:TwoZeroTwoNineteenNotesMember 2023-04-01 2023-06-30 0000730272 us-gaap:PrincipalOwnerMember 2024-04-01 2024-06-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2023-01-01 2023-06-30 0000730272 us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000730272 rgen:TwoThousandTwentyFourGrantsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0000730272 us-gaap:ProductMember srt:ScenarioPreviouslyReportedMember 2024-04-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:CustomerRelationshipsMember 2024-01-01 2024-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:TrademarksAndTradeNamesMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-31 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2024-06-30 0000730272 us-gaap:PrincipalOwnerMember 2023-04-01 2023-06-30 0000730272 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:FairValueOfEmbeddedConversionOptionMember rgen:ModifiedTwoZeroOneNineNotesMember 2024-01-01 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember 2024-01-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:TwoZeroTwoThreeNotesMember 2024-01-01 2024-06-30 0000730272 rgen:ProbabilityWeightedPresentValueMember rgen:ManufacturingLineExpansionsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember srt:MaximumMember 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ExchangedTwoZeroOneNineNotesMember 2023-12-14 0000730272 us-gaap:RetainedEarningsMember 2024-03-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000730272 rgen:TwoZeroTwoThreeNotesMember 2024-01-01 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0000730272 us-gaap:CommonStockMember 2024-03-31 0000730272 us-gaap:RetainedEarningsMember rgen:OtherAdjustmentsMember 2024-01-01 2024-06-30 0000730272 rgen:ProbabilityWeightedPresentValueMember rgen:ManufacturingLineExpansionsMember srt:MinimumMember us-gaap:FairValueMeasurementsRecurringMember rgen:ContingentConsiderationMember 2024-06-30 0000730272 srt:RestatementAdjustmentMember us-gaap:ProductMember 2024-01-01 2024-06-30 0000730272 us-gaap:ProductMember 2023-01-01 2023-06-30 0000730272 us-gaap:MeasurementInputPriceVolatilityMember rgen:MonteCarloSimulationMember rgen:RevenueAndVolumeBasedPaymentsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember srt:MinimumMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0000730272 rgen:AcceleratedDepreciationMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:NorthAmericaMember 2023-04-01 2023-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ModifiedTwoZeroOneNineNotesMember 2023-12-14 2023-12-14 0000730272 rgen:FlexbiosysIncMember us-gaap:TrademarksAndTradeNamesMember 2024-06-30 0000730272 us-gaap:LandMember 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0000730272 rgen:MonteCarloSimulationMember rgen:RevenueAndVolumeBasedPaymentsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember rgen:MeasurementInputEarnoutDiscountRateMember 2024-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000730272 us-gaap:RoyaltyMember 2024-04-01 2024-06-30 0000730272 srt:ScenarioPreviouslyReportedMember 2023-12-31 0000730272 rgen:InflationReductionActOfTwoThousandTwentyTwoMember 2021-01-01 2021-12-31 0000730272 us-gaap:EmployeeSeveranceMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000730272 rgen:FlexbiosysIncMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000730272 rgen:TwoZeroTwoThreeNotesMember 2024-06-30 0000730272 us-gaap:RetainedEarningsMember rgen:OtherAdjustmentsMember 2024-06-30 0000730272 rgen:OtherAdjustmentsMember 2024-01-01 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000730272 rgen:ManufacturingLineExpansionsMember rgen:ProbabilityWeightedPresentValueMember us-gaap:FairValueMeasurementsRecurringMember rgen:ContingentConsiderationMember 2024-06-30 0000730272 rgen:OtherAdjustmentsMember 2024-03-31 0000730272 rgen:MetenovaHoldingAbMember 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000730272 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000730272 us-gaap:PrincipalOwnerMember rgen:SpectrumIncMember srt:MinimumMember 2024-06-30 0000730272 rgen:FlexbiosysIncMember 2024-01-01 2024-06-30 0000730272 us-gaap:MoneyMarketFundsMember 2023-12-31 0000730272 srt:RestatementAdjustmentMember us-gaap:ProductMember 2024-04-01 2024-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000730272 rgen:MonteCarloSimulationMember rgen:MeasurementInputRevenueVolumeDiscountRateMember rgen:RevenueAndVolumeBasedPaymentsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000730272 us-gaap:ProductMember 2024-01-01 2024-06-30 0000730272 srt:RestatementAdjustmentMember us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0000730272 srt:ScenarioPreviouslyReportedMember 2024-04-01 2024-06-30 0000730272 rgen:AvitideLlcMember 2024-04-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember 2023-12-31 0000730272 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2023-12-31 0000730272 srt:ScenarioPreviouslyReportedMember 2024-06-30 0000730272 us-gaap:PatentsMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-19 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2023-04-01 2023-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:NoncompeteAgreementsMember 2024-06-30 0000730272 rgen:FacilityAndOtherExitCostsMember 2023-12-31 0000730272 rgen:MonteCarloSimulationMember rgen:ManufacturingLineExpansionsMember rgen:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember rgen:MeasurementInputProbabilityOfSuccessMember 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember srt:MinimumMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ScenarioPreviouslyReportedMember 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember 2023-12-31 0000730272 us-gaap:EmployeeStockOptionMember rgen:NonExecutiveMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2024-06-30 0000730272 rgen:OnePointZeroZeroPercentConvertibleSeniorNotesDueTwentyTwentyEightMember rgen:ModifiedTwoZeroOneNineNotesMember 2024-06-30 0000730272 2024-03-31 0000730272 2023-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2023-12-31 0000730272 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ScenarioPreviouslyReportedMember 2024-04-01 2024-06-30 0000730272 rgen:ContingentConsiderationMember 2023-12-31 0000730272 rgen:TwoThousandTwentyFourGrantsMember 2024-01-01 2024-06-30 0000730272 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember 2024-06-30 0000730272 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-06-30 0000730272 us-gaap:SalesRevenueNetMember srt:EuropeMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-06-30 0000730272 rgen:FlexbiosysIncMember 2023-04-17 0000730272 2024-04-01 2024-06-30 0000730272 rgen:FlexbiosysIncMember 2023-04-17 2023-04-17 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-06-30 0000730272 rgen:MetenovaHoldingAbMember us-gaap:TradeNamesMember 2024-06-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-19 2019-07-19 0000730272 rgen:MetenovaHoldingAbMember us-gaap:DevelopedTechnologyRightsMember 2024-01-01 2024-06-30 0000730272 us-gaap:ProductMember 2024-04-01 2024-06-30 0000730272 2023-01-01 2023-03-31 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-31 0000730272 rgen:OtherAdjustmentsMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000730272 rgen:AcceleratedDepreciationMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0000730272 us-gaap:MoneyMarketFundsMember 2024-06-30 0000730272 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 iso4217:USD xbrli:shares xbrli:pure xbrli:shares rgen:Segment rgen:Days iso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to___________

Commission File Number 000-14656

REPLIGEN CORP ORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware | 04-2729386
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.)
41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA | 02453
(Address of Principal Executive Offices) | (Zip Code)

(781) 250-0111

Registrant’s Telephone Number, Including Area Code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.01 per share | RGEN | The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer |  | Accelerated filer | 
Non-accelerated filer |  | Smaller reporting company | 
Emerging growth company |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock on July 26, 2024 was 56,006,498.

1

EXPLANATORY NOTE

Repligen Corporation (“we,” “us,” “our,” or the “Company”) is filing this Amendment No. 1 on Fo rm 10-Q/A (the “Amendment”) to amend and restate certain items in our Quarterly Report on Form 10-Q as of and for the three and six month periods ended June 30, 2024, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 30, 2024 (the “Original Report”), as listed in “Items Amended in this Filing” below.

In filing this Amendment, we are restating our previously issued unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 to correct the misapplication of accounting principles under U.S. GAAP related to the timing of revenue recognition arising from a specific COVID-related cancellation payment, received in connection with a contract modification (collectively, the "Misstatement"), as further described in Note 1 to the unaudited condensed consolidated financial statements herein. This restatement changes the timing of recognition of revenue, including the revenue reported in the Original Report, but will not change the total revenue to be recognized for this payment, nor have any impact on the Company’s previously reported cash and cash equivalent balances. This misapplication did not result from any override of controls, misconduct, or fraud of any kind. In connection with the restatement, the Company determined that it was appropriate to correct other unrelated immaterial errors.

In addition, we have filed an amendment to our Annual Report on Form 10-K for the year ended December 31, 2023, originally filed with SEC on February 22, 2024, and amendments to our Quarterly Reports on Form 10-Q for quarterly periods ended March 31, 2023, originally filed with the SEC on May 2, 2023; June 30, 2023, originally filed with the SEC on August 2, 2023; September 30, 2023, originally filed with the SEC on October 31, 2023; and March 31, 2024, originally filed with the SEC on May 1, 2024. In correcting the Misstatement in this Amendment, we have also restated other financial statement line item amounts including but not limited to product revenues, income tax provision, net income, foreign currency translation, deferred revenues, prepaid expenses, deferred taxes and earnings-per-share.

Internal Control Considerations

Management has reassessed its evaluation of the effectiveness of its internal control over financial reporting as of June 30, 2024, as further described in Part I, Item 4 of this Amendment, and concluded that material weaknesses existed and that internal control over financial reporting was not effective as of June 30, 2024.

Items Amended in this Filing

This Amendment amends and restates the sections of the Original Report listed below, with modifications as necessary to reflect the effects of the restatement of our previously issued condensed consolidated financial statements as of and for the three and six month periods ended June 30, 2024 and 2023. No attempt has been made in this Amendment to update other disclosures presented in the Original Report, except as required to reflect the effects of such restatement in the following amended items:

•
Part I, Item 1. Financial Statements
•
Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
•
Part I, Item 4. Controls and Procedures
•
Part II, Item 1A. Risk Factors
•
Part II, Item 6. Exhibits

Except as it relates to the restatement described above and related disclosures, this Amendment does not reflect events occurring after the date of the Original Report. Among other things, forward looking statements made in the Original Report have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Report, and such forward looking statements should be read in their historical context. As such, this Amendment speaks only as of the date the Original Report was filed, and the Company has not undertaken herein to amend, supplement or update any information contained in the Original

2

Report to give effect to any subsequent events. Accordingly, this Amendment should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Report, including any amendment to those filings.

The exhibit list included in “Part II, Item 6. Exhibits” herein has been amended to contain currently dated certifications from the Company’s Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 and filed as Exhibits 31.1, 31.2 and 32.

In accordance with applicable SEC rules, this Amendment also includes an updated signature page.

3

Table of Contents

|  |  | PAGE
PART I - | FINANCIAL INFORMATION |  |
Item 1. | Financial Statements |  |
| Condensed Consolidated Balance Sheets as of June 30, 2024 (As Restated) and December 31, 2023 (As Restated) |  | 5
| Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2024 (As Restated) and 2023 (As Restated) |  | 6
| Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 (As Restated) and 2023 (As Restated) |  | 7
| Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 (As Restated) and 2023 (As Restated) |  | 9
| Notes to Unaudited Condensed Consolidated Financial Statements (As Restated) |  | 10
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 33
Item 4. | Controls and Procedures |  | 42
PART II - | OTHER INFORMATION |  |
Item 1A. | Risk Factors |  | 45
Item 6. | Exhibits |  | 46
Signatures |  | 47

4

PART I – FINANCIAL INF ORMATION

ITEM 1. Financia l Statements

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED B AL ANCE SHEETS

(Unaudited, amounts in thousands, except share data)

|  | June 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (As Restated) |  |  | (As Restated) |
ASSETS |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 809,146 |  |  | $ | 751,323 |
Accounts receivable, net of reserves of $1,823 and $2,122 at June 30, 2024 and December 31, 2023, respectively |  |  | 123,245 |  |  |  | 124,161 |
Inventories, net |  |  | 190,528 |  |  |  | 202,321 |
Assets held for sale |  |  | 1,016 |  |  |  | — |
Prepaid expenses and other current assets |  |  | 32,830 |  |  |  | 33,541 |
Total current assets |  |  | 1,156,765 |  |  |  | 1,111,346 |
Noncurrent assets: |  |  |  |  |  |
Property, plant and equipment, net |  |  | 204,599 |  |  |  | 207,440 |
Intangible assets, net |  |  | 386,048 |  |  |  | 406,957 |
Goodwill |  |  | 985,613 |  |  |  | 987,120 |
Deferred tax assets |  |  | 678 |  |  |  | 1,530 |
Operating lease right of use assets |  |  | 131,450 |  |  |  | 115,515 |
Other noncurrent assets |  |  | 853 |  |  |  | 1,277 |
Total noncurrent assets |  |  | 1,709,241 |  |  |  | 1,719,839 |
Total assets |  | $ | 2,866,006 |  |  | $ | 2,831,185 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |
Accounts payable |  | $ | 20,910 |  |  | $ | 19,563 |
Operating lease liability |  |  | 12,129 |  |  |  | 5,631 |
Current contingent consideration |  |  | 13,936 |  |  |  | 12,983 |
Accrued liabilities |  |  | 58,349 |  |  |  | 57,313 |
Convertible Senior Notes due 2024, net |  |  | 69,481 |  |  |  | 69,452 |
Total current liabilities |  |  | 174,805 |  |  |  | 164,942 |
Noncurrent liabilities: |  |  |  |  |  |
Convertible Senior Notes due 2028, net |  |  | 517,725 |  |  |  | 510,143 |
Deferred tax liabilities |  |  | 34,044 |  |  |  | 39,324 |
Noncurrent operating lease liability |  |  | 143,518 |  |  |  | 126,578 |
Noncurrent contingent consideration |  |  | — |  |  |  | 14,070 |
Other noncurrent liabilities |  |  | 11,476 |  |  |  | 11,283 |
Total noncurrent liabilities |  |  | 706,763 |  |  |  | 701,398 |
Total liabilities |  |  | 881,568 |  |  |  | 866,340 |
Commitments and contingencies (Note 11) |  |  |  |  |  |
Stockholders' equity: |  |  |  |  |  |
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding |  |  | — |  |  |  | — |
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,902,860 shares at June 30, 2024 and 55,766,078 shares at December 31, 2023 issued and outstanding |  |  | 559 |  |  |  | 558 |
Additional paid-in capital |  |  | 1,586,447 |  |  |  | 1,569,227 |
Accumulated other comprehensive loss |  |  | (44,445 | ) |  |  | (37,808 | )
Accumulated earnings |  |  | 441,877 |  |  |  | 432,868 |
Total stockholders’ equity |  |  | 1,984,438 |  |  |  | 1,964,845 |
Total liabilities and stockholders’ equity |  | $ | 2,866,006 |  |  | $ | 2,831,185 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

REPLIGEN CORPORATION

Condensed CONSOLIDATED STATEMENT S O F COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share data)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (As Restated) |  |  | (As Restated) |  |  | (As Restated) |  |  | (As Restated) |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Product |  | $ | 158,804 |  |  | $ | 159,133 |  |  | $ | 311,950 |  |  | $ | 324,474 |
Royalty and other revenue |  |  | 35 |  |  |  | 36 |  |  |  | 71 |  |  |  | 75 |
Total revenue |  |  | 158,839 |  |  |  | 159,169 |  |  |  | 312,021 |  |  |  | 324,549 |
Costs and operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold |  |  | 77,314 |  |  |  | 79,307 |  |  |  | 153,705 |  |  |  | 161,152 |
Research and development |  |  | 10,575 |  |  |  | 9,706 |  |  |  | 21,813 |  |  |  | 21,860 |
Selling, general and administrative |  |  | 65,481 |  |  |  | 49,084 |  |  |  | 127,284 |  |  |  | 105,372 |
Contingent consideration |  |  | — |  |  |  | 1,791 |  |  |  | — |  |  |  | 3,026 |
Total costs and operating expenses |  |  | 153,370 |  |  |  | 139,888 |  |  |  | 302,802 |  |  |  | 291,410 |
Income from operations |  |  | 5,469 |  |  |  | 19,281 |  |  |  | 9,219 |  |  |  | 33,139 |
Other income (expenses): |  |  |  |  |  |  |  |  |  |  |  |
Investment income |  |  | 9,411 |  |  |  | 5,964 |  |  |  | 18,404 |  |  |  | 11,450 |
Interest expense |  |  | (5,118 | ) |  |  | (411 | ) |  |  | (10,147 | ) |  |  | (819 | )
Amortization of debt issuance costs |  |  | (520 | ) |  |  | (457 | ) |  |  | (1,003 | ) |  |  | (914 | )
Other (expenses) income |  |  | (215 | ) |  |  | 528 |  |  |  | (3,751 | ) |  |  | 605 |
Other income, net |  |  | 3,558 |  |  |  | 5,624 |  |  |  | 3,503 |  |  |  | 10,322 |
Income before income taxes |  |  | 9,027 |  |  |  | 24,905 |  |  |  | 12,722 |  |  |  | 43,461 |
Income tax provision |  |  | 3,314 |  |  |  | 5,119 |  |  |  | 3,713 |  |  |  | 8,338 |
Net income |  | $ | 5,713 |  |  | $ | 19,786 |  |  | $ | 9,009 |  |  | $ | 35,123 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.10 |  |  | $ | 0.36 |  |  | $ | 0.16 |  |  | $ | 0.63 |
Diluted (Note 13) |  | $ | 0.10 |  |  | $ | 0.35 |  |  | $ | 0.16 |  |  | $ | 0.62 |
Weighted average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 55,884 |  |  |  | 55,705 |  |  |  | 55,838 |  |  |  | 55,648 |
Diluted (Note 13) |  |  | 56,434 |  |  |  | 56,858 |  |  |  | 56,477 |  |  |  | 56,932 |
Net income |  | $ | 5,713 |  |  | $ | 19,786 |  |  | $ | 9,009 |  |  | $ | 35,123 |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  |  | (1,503 | ) |  |  | (6,079 | ) |  |  | (6,637 | ) |  |  | (3,092 | )
Comprehensive income (loss) |  | $ | 4,210 |  |  | $ | 13,707 |  |  | $ | 2,372 |  |  | $ | 32,031 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited, amounts in thousands, except share data)

|  | Three Months Ended June 30, 2024 |
|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Shares |  |  | Par Value |  |  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive Loss |  |  | Retained Earnings |  |  | Total Stockholders' Equity |
Balance at March 31, 2024, as restated |  |  | 55,841,318 |  |  | $ | 559 |  |  | $ | 1,571,811 |  |  | $ | (42,942 | ) |  | $ | 436,164 |  |  | $ | 1,965,592 |
Net income, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5,713 |  |  |  | 5,713 |
Conversion of debt |  |  | 2 |  |  |  | — |  |  |  | (53 | ) |  |  | — |  |  |  | — |  |  |  | (53 | )
Exercise of stock options and vesting of stock units |  |  | 40,560 |  |  |  | — |  |  |  | 842 |  |  |  | — |  |  |  | — |  |  |  | 842 |
Tax withholding on vesting of restricted stock units |  |  | (7,658 | ) |  |  | — |  |  |  | (1,234 | ) |  |  | — |  |  |  | — |  |  |  | (1,234 | )
Issuance of common stock pursuant to contingent consideration earnout payments |  |  | 28,638 |  |  |  | — |  |  |  | 5,202 |  |  |  | — |  |  |  | — |  |  |  | 5,202 |
Stock-based compensation expense, as restated |  |  | — |  |  |  | — |  |  |  | 9,879 |  |  |  | — |  |  |  | — |  |  |  | 9,879 |
Translation adjustment, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,503 | ) |  |  | — |  |  |  | (1,503 | )
Balance at June 30, 2024, as restated |  |  | 55,902,860 |  |  | $ | 559 |  |  | $ | 1,586,447 |  |  | $ | (44,445 | ) |  | $ | 441,877 |  |  | $ | 1,984,438 |

|  | Three Months Ended June 30, 2023 |
|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Shares |  |  | Par Value |  |  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive Loss |  |  | Retained Earnings |  |  | Total Stockholders' Equity |
Balance at March 31, 2023, as restated |  |  | 55,644,301 |  |  | $ | 556 |  |  | $ | 1,544,956 |  |  | $ | (31,407 | ) |  | $ | 412,609 |  |  | $ | 1,926,714 |
Net income, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 19,786 |  |  |  | 19,786 |
Conversion of debt |  |  | 6 |  |  |  | — |  |  |  | (3 | ) |  |  | — |  |  |  | — |  |  |  | (3 | )
Exercise of stock options and vesting of stock units |  |  | 36,184 |  |  |  | 1 |  |  |  | 32 |  |  |  | — |  |  |  | — |  |  |  | 33 |
Tax withholding on vesting of restricted stock units |  |  | (9,631 | ) |  |  | — |  |  |  | (1,547 | ) |  |  | — |  |  |  | — |  |  |  | (1,547 | )
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc. |  |  | 31,415 |  |  |  | — |  |  |  | 5,243 |  |  |  | — |  |  |  | — |  |  |  | 5,243 |
Issuance of common stock pursuant to contingent consideration earnout payments |  |  | 42,621 |  |  |  | — |  |  |  | 7,229 |  |  |  | — |  |  |  | — |  |  |  | 7,229 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | 5,483 |  |  |  | — |  |  |  | — |  |  |  | 5,483 |
Translation adjustment, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,079 | ) |  |  | — |  |  |  | (6,079 | )
Balance at June 30, 2023, as restated |  |  | 55,744,896 |  |  | $ | 557 |  |  | $ | 1,561,393 |  |  | $ | (37,486 | ) |  | $ | 432,395 |  |  | $ | 1,956,859 |

|  | Six Months Ended June 30, 2024 |
|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Shares |  |  | Par Value |  |  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive Loss |  |  | Retained Earnings |  |  | Total Stockholders' Equity |
Balance at December 31, 2023, as restated |  |  | 55,766,078 |  |  | $ | 558 |  |  | $ | 1,569,227 |  |  | $ | (37,808 | ) |  | $ | 432,868 |  |  | $ | 1,964,845 |
Net income, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 9,009 |  |  |  | 9,009 |
Conversion of debt |  |  | 2 |  |  |  | — |  |  |  | (107 | ) |  |  | — |  |  |  | — |  |  |  | (107 | )
Exercise of stock options and vesting of stock units |  |  | 152,481 |  |  |  | 2 |  |  |  | 1,786 |  |  |  | — |  |  |  | — |  |  |  | 1,788 |
Tax withholding on vesting of restricted stock units |  |  | (47,109 | ) |  |  | (1 | ) |  |  | (8,856 | ) |  |  | — |  |  |  | — |  |  |  | (8,857 | )
Issuance of common stock pursuant to contingent consideration earnout payments |  |  | 31,408 |  |  |  | — |  |  |  | 5,742 |  |  |  | — |  |  |  | — |  |  |  | 5,742 |
Stock-based compensation expense, as restated |  |  | — |  |  |  | — |  |  |  | 18,655 |  |  |  | — |  |  |  | — |  |  |  | 18,655 |
Translation adjustment, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,637 | ) |  |  | — |  |  |  | (6,637 | )
Balance at June 30, 2024, as restated |  |  | 55,902,860 |  |  | $ | 559 |  |  | $ | 1,586,447 |  |  | $ | (44,445 | ) |  | $ | 441,877 |  |  | $ | 1,984,438 |

7

|  | Six Months Ended June 30, 2023 |
|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Shares |  |  | Par Value |  |  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive Loss |  |  | Retained Earnings |  |  | Total Stockholders' Equity |
Balance at December 31, 2022 |  |  | 55,557,698 |  |  | $ | 556 |  |  | $ | 1,547,266 |  |  | $ | (34,394 | ) |  | $ | 397,272 |  |  | $ | 1,910,700 |
Net income, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 35,123 |  |  |  | 35,123 |
Conversion of debt |  |  | 6 |  |  |  | — |  |  |  | (3 | ) |  |  | — |  |  |  | — |  |  |  | (3 | )
Exercise of stock options and vesting of stock units |  |  | 176,394 |  |  |  | 2 |  |  |  | 60 |  |  |  | — |  |  |  | — |  |  |  | 62 |
Tax withholding on vesting of restricted stock units |  |  | (63,238 | ) |  |  | (1 | ) |  |  | (11,139 | ) |  |  | — |  |  |  | — |  |  |  | (11,140 | )
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc. |  |  | 31,415 |  |  |  | — |  |  |  | 5,243 |  |  |  | — |  |  |  | — |  |  |  | 5,243 |
Issuance of common stock pursuant to the contingent consideration earnout payments |  |  | 42,621 |  |  |  | — |  |  |  | 7,229 |  |  |  | — |  |  |  | — |  |  |  | 7,229 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | 12,737 |  |  |  | — |  |  |  | — |  |  |  | 12,737 |
Translation adjustment, as restated |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,092 | ) |  |  | — |  |  |  | (3,092 | )
Balance at June 30, 2023, as restated |  |  | 55,744,896 |  |  | $ | 557 |  |  | $ | 1,561,393 |  |  | $ | (37,486 | ) |  | $ | 432,395 |  |  | $ | 1,956,859 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATE MENTS OF CASH FLOWS

(Unaudited, amounts in thousands)

|  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |
|  | (As Restated) |  |  | (As Restated) |
Cash flows from operating activities: |  |  |  |  |  |
Net income |  | $ | 9,009 |  |  | $ | 35,123 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |
Depreciation and amortization |  |  | 33,884 |  |  |  | 31,473 |
Amortization of debt discount and issuance costs |  |  | 7,727 |  |  |  | 914 |
Stock-based compensation |  |  | 18,655 |  |  |  | 12,737 |
Deferred income taxes, net |  |  | (3,753 | ) |  |  | (2,053 | )
Contingent consideration |  |  | — |  |  |  | 3,026 |
Non-cash interest income |  |  | — |  |  |  | (2,023 | )
Operating lease right of use asset amortization* |  |  | 8,716 |  |  |  | 6,487 |
Other |  |  | 103 |  |  |  | 849 |
Changes in operating assets and liabilities, excluding impact of acquisitions: |  |  |  |  |  |
Accounts receivable |  |  | (1,245 | ) |  |  | (4,606 | )
Inventories |  |  | 10,474 |  |  |  | (2,508 | )
Prepaid expenses and other assets |  |  | 457 |  |  |  | (12,879 | )
Other assets |  |  | 364 |  |  |  | (888 | )
Accounts payable |  |  | 1,547 |  |  |  | (3,871 | )
Accrued expenses |  |  | 2,259 |  |  |  | (11,769 | )
Operating lease liabilities |  |  | (1,198 | ) |  |  | (4,544 | )
Long-term liabilities |  |  | (101 | ) |  |  | 154 |
Total cash provided by operating activities |  |  | 86,898 |  |  |  | 45,622 |
Cash flows from investing activities: |  |  |  |  |  |
Acquisitions, net of cash acquired |  |  | — |  |  |  | (28,099 | )
Proceeds from maturity of marketable securities held to maturity |  |  | — |  |  |  | 102,323 |
Additions to capitalized software costs |  |  | (2,619 | ) |  |  | (2,075 | )
Purchases of property, plant and equipment |  |  | (13,154 | ) |  |  | (16,749 | )
Other investing activities |  |  | 11 |  |  |  | — |
Total cash (used in) provided by investing activities |  |  | (15,762 | ) |  |  | 55,400 |
Cash flows from financing activities: |  |  |  |  |  |
Proceeds from exercise of stock options |  |  | 1,788 |  |  |  | 62 |
Payment of tax withholding obligation on vesting of restricted stock |  |  | (8,857 | ) |  |  | (11,140 | )
Payment of earnout consideration |  |  | (7,375 | ) |  |  | (7,298 | )
Other financing activities |  |  | (303 | ) |  |  | (12 | )
Total cash used in financing activities |  |  | (14,747 | ) |  |  | (18,388 | )
Effect of exchange rate changes on cash and cash equivalents |  |  | 1,434 |  |  |  | (2,436 | )
Net increase in cash and cash equivalents |  |  | 57,823 |  |  |  | 80,198 |
Cash, cash equivalents, beginning of period |  |  | 751,323 |  |  |  | 523,458 |
Cash and cash equivalents, end of period |  | $ | 809,146 |  |  | $ | 603,656 |
Supplemental disclosure of non-cash investing and financing activities: |  |  |  |  |  |
Assets acquired under operating leases |  | $ | 23,860 |  |  | $ | 831 |
Fair value of shares of common stock issued for contingent consideration earnouts |  | $ | 5,742 |  |  | $ | 7,229 |
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc. |  | $ | — |  |  | $ | 5,243 |

*Amounts reclassified in the current presentation from a component of “Changes in operating assets and liabilities” to a component of “Adjustments to reconcile net income.” The reclassification did not result in any change to total cash provided by operating activities.

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

REPLIGEN CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.
Restatement of Previously Issued Financial Statements

Subsequent to the issuance of the Original Report on July 30, 2024, the Company identified a material accounting error related to the timing of revenue recognition which impacts the Company’s condensed consolidated financial statements as of and for the three and six month periods ended June 30, 2024 and 2023 ("the Misstatement"). Within this report, the Company has restated all impacted financial information and footnote disclosures impacted by the Misstatement. A description of the error and its impact on the previously issued financial statements is included below. In connection with the restatement to correct this misstatement, the Company determined that it was appropriate to correct other unrelated immaterial errors.

Description of revenue restatement adjustments

During the first quarter of 2023, a customer cancelled two COVID-related, non-cancellable product purchase orders (“Cancelled PO’s”) in exchange for a $17.3 million one-time cash payment (the “Payment”), which was received in April 2023. At the time of cancellation, no product units had been delivered under the Cancelled PO’s and the Company had two other purchase orders from the same customer for the same product (“Open PO’s”). The Company originally accounted for the Cancelled PO’s as a single contract and recognized the $17.3 million payment as component of product revenue in the first quarter of 2023.

Subsequent to the issuance of the Original Report, the Company reassessed the accounting treatment of the Payment and concluded that the Cancelled PO’s and Open PO’s represented a combined contract such that the February 2023 transaction should have been analyzed and accounted for as a contract modification, which required the Payment to be deferred and recognized as product units were delivered under the Open PO’s. All Open PO product units were fully delivered to the customer by June 30, 2024.

The correction of the Misstatement affects certain financial statement line items in these condensed consolidated financial statements including but not limited to product revenues, income tax provision, foreign currency translation, deferred revenues, prepaid expenses, deferred taxes and earnings-per-share.

Consolidated Financial Statements - Restatement Reconciliation Tables

The following tables present the impact of the financial statement adjustments on the Company's previously reported condensed consolidated financial statements. The "Previously Reported" amounts in the following tables are amounts derived from the Original Report. The amounts in the columns labeled "Revenue Adjustments" represent the effect of adjustments resulting from the correction of the overstatement of revenues associated with the Payment and related tax impact. The amounts in the columns labeled "Other Adjustments" represent the effect of other adjustments that relate to other unrelated errors in previously filed financial statements that were not material, individually or in the aggregate, to those filed financial statements. The effects of both the restatement for the Revenue Adjustments and the immaterial Other Adjustments have been corrected in all impacted tables and footnotes throughout these condensed consolidated financial statements.

10

|  | June 30, |
|  | 2024 |
|  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |
ASSETS |  |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 809,146 |  |  | $ | — |  |  | $ | — |  |  | $ | 809,146 |
Accounts receivable, net of reserves of $1,823 and $2,122 at June 30, 2024 and December 31, 2023, respectively |  |  | 123,245 |  |  |  | — |  |  |  | — |  |  |  | 123,245 |
Inventories, net |  |  | 190,528 |  |  |  | — |  |  |  | — |  |  |  | 190,528 |
Assets held for sale |  |  | 1,016 |  |  |  | — |  |  |  | — |  |  |  | 1,016 |
Prepaid expenses and other current assets |  |  | 34,983 |  |  |  | (2,397 | ) |  |  | 244 |  |  |  | 32,830 |
Total current assets |  |  | 1,158,918 |  |  |  | (2,397 | ) |  |  | 244 |  |  |  | 1,156,765 |
Noncurrent assets: |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  |  | 204,599 |  |  |  | — |  |  |  | — |  |  |  | 204,599 |
Intangible assets, net |  |  | 379,813 |  |  |  | — |  |  |  | 6,235 |  |  |  | 386,048 |
Goodwill |  |  | 985,613 |  |  |  | — |  |  |  | — |  |  |  | 985,613 |
Deferred tax assets |  |  | 678 |  |  |  | — |  |  |  | — |  |  |  | 678 |
Operating lease right of use assets |  |  | 131,450 |  |  |  | — |  |  |  | — |  |  |  | 131,450 |
Other noncurrent assets |  |  | 853 |  |  |  | — |  |  |  | — |  |  |  | 853 |
Total noncurrent assets |  |  | 1,703,006 |  |  |  | — |  |  |  | 6,235 |  |  |  | 1,709,241 |
Total assets |  | $ | 2,861,924 |  |  | $ | (2,397 | ) |  | $ | 6,479 |  |  | $ | 2,866,006 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  | $ | 20,910 |  |  | $ | — |  |  | $ | — |  |  | $ | 20,910 |
Operating lease liability |  |  | 12,129 |  |  |  | — |  |  |  | — |  |  |  | 12,129 |
Current contingent consideration |  |  | 13,936 |  |  |  | — |  |  |  | — |  |  |  | 13,936 |
Accrued liabilities |  |  | 57,851 |  |  |  | 498 |  |  |  | — |  |  |  | 58,349 |
Convertible Senior Notes due 2024, net |  |  | 69,481 |  |  |  | — |  |  |  | — |  |  |  | 69,481 |
Total current liabilities |  |  | 174,307 |  |  |  | 498 |  |  |  | — |  |  |  | 174,805 |
Noncurrent liabilities: |  |  |  |  |  |  |  |  | — |  |  |  |
Convertible Senior Notes due 2028, net |  |  | 517,725 |  |  |  | — |  |  |  | — |  |  |  | 517,725 |
Deferred tax liabilities |  |  | 36,305 |  |  |  | (1,903 | ) |  |  | (358 | ) |  |  | 34,044 |
Noncurrent operating lease liability |  |  | 143,518 |  |  |  | — |  |  |  | — |  |  |  | 143,518 |
Noncurrent contingent consideration |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Other noncurrent liabilities |  |  | 3,707 |  |  |  | — |  |  |  | 7,769 |  |  |  | 11,476 |
Total noncurrent liabilities |  |  | 701,255 |  |  |  | (1,903 | ) |  |  | 7,411 |  |  |  | 706,763 |
Total liabilities |  |  | 875,562 |  |  |  | (1,405 | ) |  |  | 7,411 |  |  |  | 881,568 |
Commitments and contingencies (Note 11) |  |  |  |  |  |  |  |  |  |  |  |
Stockholders' equity: |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,902,860 shares at June 30, 2024 and 55,766,078 shares at December 31, 2023 issued and outstanding |  |  | 559 |  |  |  | — |  |  |  | — |  |  |  | 559 |
Additional paid-in capital |  |  | 1,585,782 |  |  |  | — |  |  |  | 665 |  |  |  | 1,586,447 |
Accumulated other comprehensive loss |  |  | (44,243 | ) |  |  | (202 | ) |  |  | — |  |  |  | (44,445 | )
Accumulated earnings |  |  | 444,264 |  |  |  | (790 | ) |  |  | (1,597 | ) |  |  | 441,877 |
Total stockholders’ equity |  |  | 1,986,362 |  |  |  | (992 | ) |  |  | (932 | ) |  |  | 1,984,438 |
Total liabilities and stockholders’ equity |  | $ | 2,861,924 |  |  | $ | (2,397 | ) |  | $ | 6,479 |  |  | $ | 2,866,006 |

11

|  | Three Months Ended June 30, 2024 |  |  | Six Months Ended June 30, 2024 |
|  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product |  | $ | 154,038 |  |  | $ | 4,766 |  |  | $ | — |  |  | $ | 158,804 |  |  | $ | 305,348 |  |  | $ | 6,602 |  |  | $ | — |  |  | $ | 311,950 |
Royalty and other revenue |  |  | 35 |  |  |  | — |  |  |  | — |  |  |  | 35 |  |  |  | 71 |  |  |  | — |  |  |  | — |  |  |  | 71 |
Total revenue |  |  | 154,073 |  |  |  | 4,766 |  |  |  | — |  |  |  | 158,839 |  |  |  | 305,419 |  |  |  | 6,602 |  |  |  | — |  |  |  | 312,021 |
Costs and operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold |  |  | 77,314 |  |  |  | — |  |  |  | — |  |  |  | 77,314 |  |  |  | 153,705 |  |  |  | — |  |  |  | — |  |  |  | 153,705 |
Research and development |  |  | 10,575 |  |  |  | — |  |  |  | — |  |  |  | 10,575 |  |  |  | 21,813 |  |  |  | — |  |  |  | — |  |  |  | 21,813 |
Selling, general and administrative |  |  | 64,697 |  |  |  | — |  |  |  | 784 |  |  |  | 65,481 |  |  |  | 126,383 |  |  |  | — |  |  |  | 901 |  |  |  | 127,284 |
Contingent consideration |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Total costs and operating expenses |  |  | 152,586 |  |  |  | — |  |  |  | 784 |  |  |  | 153,370 |  |  |  | 301,901 |  |  |  | — |  |  |  | 901 |  |  |  | 302,802 |
Income from operations |  |  | 1,487 |  |  |  | 4,766 |  |  |  | (784 | ) |  |  | 5,469 |  |  |  | 3,518 |  |  |  | 6,602 |  |  |  | (901 | ) |  |  | 9,219 |
Other income (expenses): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment income |  |  | 9,411 |  |  |  | — |  |  |  | — |  |  |  | 9,411 |  |  |  | 18,404 |  |  |  | — |  |  |  | — |  |  |  | 18,404 |
Interest expense |  |  | (4,981 | ) |  |  | — |  |  |  | (137 | ) |  |  | (5,118 | ) |  |  | (9,872 | ) |  |  | — |  |  |  | (275 | ) |  |  | (10,147 | )
Amortization of debt issuance costs |  |  | (520 | ) |  |  | — |  |  |  | — |  |  |  | (520 | ) |  |  | (1,003 | ) |  |  | — |  |  |  | — |  |  |  | (1,003 | )
Other (expenses) income |  |  | (215 | ) |  |  | — |  |  |  | — |  |  |  | (215 | ) |  |  | (3,751 | ) |  |  | — |  |  |  | — |  |  |  | (3,751 | )
Other income, net |  |  | 3,695 |  |  |  | — |  |  |  | (137 | ) |  |  | 3,558 |  |  |  | 3,778 |  |  |  | — |  |  |  | (275 | ) |  |  | 3,503 |
Income before income taxes |  |  | 5,182 |  |  |  | 4,766 |  |  |  | (921 | ) |  |  | 9,027 |  |  |  | 7,296 |  |  |  | 6,602 |  |  |  | (1,176 | ) |  |  | 12,722 |
Income tax provision |  |  | 1,861 |  |  |  | 1,757 |  |  |  | (304 | ) |  |  | 3,314 |  |  |  | 1,881 |  |  |  | 2,195 |  |  |  | (363 | ) |  |  | 3,713 |
Net income |  | $ | 3,321 |  |  | $ | 3,009 |  |  | $ | (617 | ) |  | $ | 5,713 |  |  | $ | 5,415 |  |  | $ | 4,407 |  |  | $ | (813 | ) |  | $ | 9,009 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.06 |  |  | $ | 0.05 |  |  | $ | (0.01 | ) |  | $ | 0.10 |  |  | $ | 0.10 |  |  | $ | 0.08 |  |  | $ | (0.02 | ) |  | $ | 0.16 |
Diluted (Note 13) |  | $ | 0.06 |  |  | $ | 0.05 |  |  | $ | (0.01 | ) |  | $ | 0.10 |  |  | $ | 0.10 |  |  | $ | 0.08 |  |  | $ | (0.02 | ) |  | $ | 0.16 |
Weighted average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 55,884 |  |  |  | — |  |  |  | — |  |  |  | 55,884 |  |  |  | 55,838 |  |  |  | — |  |  |  | — |  |  |  | 55,838 |
Diluted (Note 13) |  |  | 56,434 |  |  |  | — |  |  |  | — |  |  |  | 56,434 |  |  |  | 56,477 |  |  |  | — |  |  |  | — |  |  |  | 56,477 |
Net income |  | $ | 3,321 |  |  | $ | 3,009 |  |  | $ | (617 | ) |  | $ | 5,713 |  |  | $ | 5,415 |  |  | $ | 4,407 |  |  | $ | (813 | ) |  | $ | 9,009 |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  |  | (1,531 | ) |  |  | 28 |  |  |  | — |  |  |  | (1,503 | ) |  |  | (6,812 | ) |  |  | 175 |  |  |  | — |  |  |  | (6,637 | )
Comprehensive income (loss) |  | $ | 1,790 |  |  | $ | 3,037 |  |  | $ | (617 | ) |  | $ | 4,210 |  |  | $ | (1,397 | ) |  | $ | 4,582 |  |  | $ | (813 | ) |  | $ | 2,372 |

|  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive Loss |  |  | Accumulated Earnings |  |  | Total Stockholders' Equity |
|  | As Previously Reported |  |  | Other Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |
|  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |
Balance at March 31, 2024 |  |  | 1,571,811 |  |  |  | — |  |  |  | 1,571,811 |  |  |  | (42,712 | ) |  |  | (230 | ) |  |  | (42,942 | ) |  |  | 440,943 |  |  |  | (3,799 | ) |  |  | (980 | ) |  |  | 436,164 |  |  |  | 1,970,601 |  |  |  | (4,029 | ) |  |  | (980 | ) |  |  | 1,965,592 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,321 |  |  |  | 3,009 |  |  |  | (617 | ) |  |  | 5,713 |  |  |  | 3,321 |  |  |  | 3,009 |  |  |  | (617 | ) |  |  | 5,713 |
Stock-based compensation expense |  |  | 9,214 |  |  |  | 665 |  |  |  | 9,879 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 9,214 |  |  |  | — |  |  |  | 665 |  |  |  | 9,879 |
Translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,531 | ) |  |  | 28 |  |  |  | (1,503 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,531 | ) |  |  | 28 |  |  |  | — |  |  |  | (1,503 | )
Balance at June 30, 2024 |  |  | 1,585,782 |  |  |  | 665 |  |  |  | 1,586,447 |  |  |  | (44,243 | ) |  |  | (202 | ) |  |  | (44,445 | ) |  |  | 444,264 |  |  |  | (790 | ) |  |  | (1,597 | ) |  |  | 441,877 |  |  |  | 1,986,362 |  |  |  | (992 | ) |  |  | (932 | ) |  |  | 1,984,438 |

12

|  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive Loss |  |  | Accumulated Earnings |  |  | Total Stockholders' Equity |
|  | As Previously Reported |  |  | Other Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |  |  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |
|  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |
Balance at December 31, 2023 |  |  | 1,569,227 |  |  |  | — |  |  |  | 1,569,227 |  |  |  | (37,431 | ) |  |  | (377 | ) |  |  | (37,808 | ) |  |  | 438,849 |  |  |  | (5,197 | ) |  |  | (784 | ) |  |  | 432,868 |  |  |  | 1,971,203 |  |  |  | (5,574 | ) |  |  | (784 | ) |  |  | 1,964,845 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5,415 |  |  |  | 4,407 |  |  |  | (813 | ) |  |  | 9,009 |  |  |  | 5,415 |  |  |  | 4,407 |  |  |  | (813 | ) |  |  | 9,009 |
Stock-based compensation expense |  |  | 17,990 |  |  |  | 665 |  |  |  | 18,655 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 17,990 |  |  |  | — |  |  |  | 665 |  |  |  | 18,655 |
Translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,812 | ) |  |  | 175 |  |  |  | (6,637 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,812 | ) |  |  | 175 |  |  |  | — |  |  |  | (6,637 | )
Balance at June 30, 2024 |  |  | 1,585,782 |  |  |  | 665 |  |  |  | 1,586,447 |  |  |  | (44,243 | ) |  |  | (202 | ) |  |  | (44,445 | ) |  |  | 444,264 |  |  |  | (790 | ) |  |  | (1,597 | ) |  |  | 441,877 |  |  |  | 1,986,362 |  |  |  | (992 | ) |  |  | (932 | ) |  |  | 1,984,438 |

|  | Six Months Ended June 30, 2024 |
|  | As Previously Reported |  |  | Revenue Adjustments |  |  | Other Adjustments |  |  | As Restated |
Cash flows from operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 5,415 |  |  | $ | 4,407 |  |  | $ | (813 | ) |  | $ | 9,009 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 33,648 |  |  |  | — |  |  |  | 236 |  |  |  | 33,884 |
Amortization of debt discount and issuance costs |  |  | 7,727 |  |  |  | — |  |  |  | — |  |  |  | 7,727 |
Stock-based compensation |  |  | 17,990 |  |  |  | — |  |  |  | 665 |  |  |  | 18,655 |
Deferred income taxes, net |  |  | (2,634 | ) |  |  | (1,000 | ) |  |  | (119 | ) |  |  | (3,753 | )
Operating lease right of use asset amortization |  |  | (16,349 | ) |  |  | — |  |  |  | 25,065 |  |  |  | 8,716 |
Other |  |  | (172 | ) |  |  | — |  |  |  | 275 |  |  |  | 103 |
Changes in operating assets and liabilities, excluding impact of acquisitions: |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  | (1,245 | ) |  |  | — |  |  |  | — |  |  |  | (1,245 | )
Inventories |  |  | 10,474 |  |  |  | — |  |  |  | — |  |  |  | 10,474 |
Prepaid expenses and other assets |  |  | (1,999 | ) |  |  | 2,700 |  |  |  | (244 | ) |  |  | 457 |
Other assets |  |  | 364 |  |  |  | — |  |  |  | — |  |  |  | 364 |
Accounts payable |  |  | 1,547 |  |  |  | — |  |  |  | — |  |  |  | 1,547 |
Accrued expenses |  |  | 8,366 |  |  |  | (6,107 | ) |  |  | — |  |  |  | 2,259 |
Operating lease liabilities |  |  | 23,867 |  |  |  | — |  |  |  | (25,065 | ) |  |  | (1,198 | )
Long-term liabilities |  |  | (101 | ) |  |  | — |  |  |  | — |  |  |  | (101 | )
Total cash provided by operating activities |  |  | 86,898 |  |  |  | — |  |  |  | — |  |  |  | 86,898 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions to capitalized software costs |  |  | (2,619 | ) |  |  | — |  |  |  | — |  |  |  | (2,619 | )
Purchases of property, plant and equipment |  |  | (13,154 | ) |  |  | — |  |  |  | — |  |  |  | (13,154 | )
Other investing activities |  |  | 11 |  |  |  | — |  |  |  | — |  |  |  | 11 |
Total cash (used in) provided by investing activities |  |  | (15,762 | ) |  |  | — |  |  |  | — |  |  |  | (15,762 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from exercise of stock options |  |  | 1,788 |  |  |  | — |  |  |  | — |  |  |  | 1,788 |
Payment of tax withholding obligation on vesting of restricted stock |  |  | (8,857 | ) |  |  | — |  |  |  | — |  |  |  | (8,857 | )
Payment of earnout consideration |  |  | (7,375 | ) |  |  | — |  |  |  | — |  |  |  | (7,375 | )
Other financing activities |  |  | (303 | ) |  |  | — |  |  |  | — |  |  |  | (303 | )
Total cash used in financing activities |  |  | (14,747 | ) |  |  | — |  |  |  | — |  |  |  | (14,747 | )
Effect of exchange rate changes on cash and cash equivalents |  |  | 1,434 |  |  |  | — |  |  |  | — |  |  |  | 1,434 |
Net increase in cash and cash equivalents |  |  | 57,823 |  |  |  | — |  |  |  | — |  |  |  | 57,823 |
Cash, cash equivalents, beginning of period |  |  | 751,323 |  |  |  | — |  |  |  | — |  |  |  | 751,323 |
Cash and cash equivalents, end of period |  | $ | 809,146 |  |  | $ | — |  |  | $ | — |  |  | $ | 809,146 |
Supplemental disclosure of non-cash investing and financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Assets acquired under operating leases |  | $ | 23,860 |  |  | $ | — |  |  | $ | — |  |  | $ | 23,860 |
Fair value of shares of common stock issued for contingent consideration earnouts |  | $ | 5,742 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,742 |

2.
Summary of Significant Accounting Policies

13

Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by Repligen Corporation in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended, which was filed with the SEC on November 18, 2024 (“Form 10-K/A”).

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from global geopolitical conflicts, supply chain challenges, cost pressure and the overall effects of the current inflationary environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K/A. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of June 30, 2024, its results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.

Assets Held for Sale

An asset is considered to be held for sale when all the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv) actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi) the asset is actively being marketed for sale at a price that is reasonable given its current market value.

Recent Accounting Guidance

The Company considers the applicability and impact of all Accounting Standards Updates (“ASU” or “ASUs”) and other recently issued guidance or rule decisions on their condensed consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial position or results of operations. Recently issued accounting guidance that the Company feels may be applicable to them is as follows:

Recently Issued Accounting Guidance – Not Yet Adopted

In March 2024, the SEC adopted final rules under SEC Release No. 33-11275 requiring public companies to provide certain climate-related information in their registration statements and annual reports. As part of the disclosures, registrants will be required to quantify certain effects of severe weather events and other natural conditions in a note to their audited financial statements. The rules were immediately challenged in a number of lawsuits, which were subsequently consolidated by the U.S. Court of Appeals for the Eighth Circuit. In April 2024, the SEC announced that it is staying implementation of the new rules pending resolution of the consolidated litigation before the Eighth Circuit. The Company is assessing the effect of compliance with the new rules on its condensed consolidated financial statements and related disclosures.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.” ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in

14

its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. Besides a change in income tax disclosures, the Company does not expect the adoption of ASU 2023-09 to have a material impact on its condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, “S egment Reporting (Topic 820) - Improvements to Reportable Segment Disclosures.” ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced annual and interim disclosures about significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”). The disclosures required under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 will be effective for the Company for annual periods beginning on January 1, 2024 and interim periods beginning on January 1, 2025. The amendments of this guidance apply retrospectively to all prior periods presented in the condensed consolidated financial statements. Early adoption is permitted. Besides presentation in the segment footnote for its interim reporting, the Company does not expect the adoption of ASU 2023-07 to have a material impact on its condensed consolidated financial statements.

3.
Fair Value Measurements

The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1 - | Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
Level 2 - | Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities.
Level 3 - | Valuations based on inputs that are unobservable or significant to the overall fair value measurement.

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2024 and December 31, 2023 (amounts in thousands):

|  | As of June 30, 2024 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Money market accounts |  | $ | 735,008 |  |  | $ | — |  |  | $ | — |  |  | $ | 735,008 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Short-term contingent consideration |  | $ | — |  |  | $ | — |  |  | $ | 13,936 |  |  | $ | 13,936 |
|  | As of December 31, 2023 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Money market accounts |  | $ | 658,574 |  |  | $ | — |  |  | $ | — |  |  | $ | 658,574 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Short-term contingent consideration |  | $ | — |  |  | $ | — |  |  | $ | 12,983 |  |  | $ | 12,983 |
Long-term contingent consideration |  | $ | — |  |  | $ | — |  |  | $ | 14,070 |  |  | $ | 14,070 |

Cash and cash equivalents

15

As of June 30, 2024 and December 31, 2023, cash and cash equivalents on the Company's condensed consolidated balance sheets included $735.0 million and $658.6 million, respectively, in money market accounts. These funds are valued on a recurring basis using Level 1 inputs.

Contingent Consideration – Earnouts

As of June 30, 2024, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay in connection with completed acquisitions is: $125.0 million over a three-year earnout period for Avitide, Inc. (“Avitide”), which was acquired in September 2021 and for which the earnout periods run from January 1, 2022 through December 31, 2024; $42.0 million over a two-year earnout period for FlexBiosys, Inc. (“FlexBiosys”), which was acquired in April 2023 and for which the earnout periods run from January 1, 2023 through December 31, 2024; and approximately $10 million over a one-year earnout period for Metenova Holding AB (“Metenova”), which was acquired in October 2023 and for which the earnout period runs from January 1, 2024 through December 31, 2024. See Note 4, “Acquisitions” to this report for additional information on the contingent consideration earnouts.

Since the date of acquisition, expected results and changes in market inputs used to calculate the discount rate related to Avitide, FlexBiosys and Metenova, have, at times, resulted in changes in amounts reported as the Company’s contingent consideration obligation. As of June 30, 2024, management assessed the remaining contingent consideration obligation balances and the existing market inputs used and decided that no changes in fair value were required. A reconciliation of the change in the fair value of contingent consideration – earnouts is included in the following table (amounts in thousands):

Balance at December 31, 2023 |  | $ | 27,053 |
Payment of contingent consideration earnouts |  |  | (13,117 | )
Decrease in fair value of contingent consideration earnouts |  |  | — |
Balance at June 30, 2024 |  | $ | 13,936 |

The recurring Level 3 fair value measurement of our contingent consideration obligations for Avitide, FlexBiosys and Metenova include the following significant unobservable inputs (amounts in thousands, except percent data):

Contingent Consideration Earnout |  | Fair Value as of June 30, 2024 |  |  | Valuation Technique |  | Unobservable Input |  | Range |  | Weighted Average(1)
|  |  |  |  |  |  |  | Probability of |  |  |  |
|  |  |  |  |  |  |  | Success |  | 100% |  | 100%
Commercialization-based payments |  | $ |  | 9,678 |  |  | Monte Carlo Simulation |  | Earnout Discount Rate |  | 5.8%-5.9% |  | 5.9%
|  |  |  |  |  |  |  | Volatility |  | 12.5%-24.6% |  | 13.9%
Revenue and Volume- based payments |  | $ |  | 361 |  |  | Monte Carlo Simulation |  | Revenue & Volume Discount Rate |  | 2.5%-9.3% |  | 5.1%
|  |  |  |  |  |  |  | Earnout Discount Rate |  | 5.8%-7.2% |  | 5.8%
|  |  |  |  |  |  |  | Probability of Success |  | 100% |  | 100%
Manufacturing line expansions |  | $ |  | 3,897 |  |  | Probability-weighted present value |  | Earnout Discount Rate |  | 6.1%-6.4% |  | 6.3%

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Fair Value Measured on a Nonrecurring Basis

During the three and six months ended June 30, 2024, there were no re-measurements to the fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis.

Convertible Senior Notes

In July 2019, the Company issued $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “2019 Notes”). Interest is payable semi-annually in arrears on January 15 and July 15 of each year. The 2019 Notes matured on

16

July 15, 2024. At June 30, 2024 and December 31, 2023, respectively, the carrying value of the 2019 Notes was $69.5 million, net of unamortized debt issuance costs and the fair value of the 2019 Notes was $82.6 million and $109.8 million, respectively.

On December 14, 2023, the Company issued $600.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “2023 Notes”) in a private placement pursuant to separate, privately negotiated exchange and subscription agreements (the “Exchange and Subscription Agreements”) with a limited number of holders of its outstanding 2019 Notes and certain other qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (“Securities Act”). Pursuant to the Exchange and Subscription Agreements, the Company exchanged $217.7 million of its 2019 Notes for $309.9 million aggregate principal amount of the 2023 Notes (the “Exchange Transaction”) and issued $290.1 million aggregate principal amount of the 2023 Notes (the “Subscription Transactions”) for $290.1 million in cash. At June 30, 2024 and December 31, 2023, the carrying value of the 2023 Notes was $517.7 million and $510.1 million, respectively, net of unamortized debt discount and debt issuance cost and the fair value of the 2023 Notes was $497.4 million and $596.0 million, respectively.

The fair value of the 2023 Notes and the 2019 Notes is a Level 1 valuation and was determined based on the most recent trade activity of the 2023 Notes and 2019 Notes as of June 30, 2024 and December 31, 2023. The 2023 Notes and 2019 Notes are discussed in more detail in Note 9, “Convertible Senior Notes,” to these condensed consolidated financial statements.

4.
Acquisitions

Metenova Holding AB

On October 2, 2023, the Company's subsidiary, Repligen Sweden AB, acquired Metenova from the former shareholders of Metenova (the “Metenova Seller”) pursuant to a Share Sale and Purchase Agreement (the “Share Purchase Agreement”), dated as of September 23, 2023 (such acquisition, the “Metenova Acquisition”), by and among Repligen Sweden AB, the Metenova Seller, and the Company, in its capacity as guarantor of the obligations of Repligen Sweden AB under the Share Purchase Agreement.

Metenova, which is headquartered in Molndal, Sweden, offers magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations. The Metenova Acquisition further strengthens our fluid management portfolio with these products.

Consideration Transferred

The Company accounted for the Metenova Acquisition as a purchase of business under Accounting Standards Codification (“ASC”) 805, “Business Combinations,” and the Company engaged a third-party valuation firm to assist with the valuation of Metenova. Under the Share Purchase Agreement, all outstanding equity interests of Metenova were acquired for consideration with a value totaling $172.6 million. The Metenova Acquisition was funded through payment of $164.5 million in cash, the issuance of 52,299 unregistered shares of the Company's common stock totaling $8.1 million and contingent consideration with an immaterial fair value.

Under the acquisition method of accounting, the assets acquired and liabilities assumed of Metenova were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net liabilities acquired is estimated to be $1.9 million, the fair value of the intangible assets acquired is estimated to be $58.8 million and the residual goodwill is estimated to be $115.7 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $6.1 million of transaction and integration costs associated with the Metenova Acquisition from the date of acquisition to June 30, 2024, with $1.0 million and $2.6 million o f transaction and integration costs incurred during the three and six months ended June 30, 2024, respectively. The transaction costs are included in operating expenses in the condensed consolidated statements of comprehensive income (loss) for the period ended June 30, 2024.

Fair Value of Net Assets Acquired

The preliminary allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date. As of June 30, 2024, the purchase accounting for this acquisition had not been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period. During 2024, the Company recorded a net working capital adjustment of $0.1 million related to an

17

inventory adjustment, offset in goodwill, to align the Metenova opening balance sheet. Besides tax implications of the purchase price allocation, the final allocation may result in additional changes to other assets and liabilities.

The components and estimated allocation of the purchase price consist of the following (amounts in thousands):

Cash and cash equivalents |  | $ | 5,768 |
Accounts receivable |  |  | 3,730 |
Inventory |  |  | 4,477 |
Prepaid expenses and other current assets |  |  | 470 |
Property and equipment |  |  | 433 |
Operating lease right of use asset |  |  | 615 |
Customer relationships |  |  | 12,659 |
Developed technology |  |  | 44,377 |
Trademark and tradename |  |  | 939 |
Non-competition agreements |  |  | 787 |
Goodwill |  |  | 115,722 |
Accounts payable |  |  | (1,432 | )
Accrued liabilities |  |  | (2,934 | )
Operating lease liability |  |  | (275 | )
Noncurrent deferred tax liability |  |  | (12,481 | )
Noncurrent operating lease liability |  |  | (255 | )
Fair value of net assets acquired |  | $ | 172,600 |

Acquired Goodwill

The goodwill of $115.7 million represents future economic benefits expected to arise from anticipated synergies from the integration of Metenova into the Company. These synergies include operating efficiencies and strategic benefits projected to be achieved as a result of the Metenova Acquisition. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes.

Intangible Assets

The following table sets forth the components of the identified intangible assets associated with the Metenova Acquisition and their estimated useful lives:

|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Customer relationships |  | 15 years |  | $ | 12,659 |
Developed technology |  | 15 years |  |  | 44,377 |
Trademark and tradename |  | 15 years |  |  | 939 |
Non-competition agreements |  | 2 years |  |  | 787 |
|  |  |  | $ | 58,762 |

FlexBiosys, Inc.

On April 17, 2023, the Company completed its acquisition of all of the outstanding equity interests in FlexBiosys, pursuant to an Equity Purchase Agreement (the “FlexBiosys Agreement”) with FlexBiosys, TSAP Holdings Inc. (“NJ Seller”), Gayle Tarry and Stanley Tarry, as individuals (collectively with NJ Seller, the "Sellers"), and Stanley Tarry, in his capacity as the representative of the Sellers (the “FlexBiosys Acquisition”).

FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies. These products will complement and expand our fluid management portfolio of offerings.

Consideration transferred

The FlexBiosys Acquisition was accounted for as a purchase of a business under ASC 805, and the Company engaged a third-party valuation firm to assist with the valuation of FlexBiosys. Under the terms of the FlexBiosys Agreement, all outstanding equity interests of FlexBiosys were acquired for consideration with a value totaling $41.0 million. The FlexBiosys Acquisition was funded through payment of $29.0 million in cash, which includes $6.3 million deposited in escrow for future payments, the

18

issuance of 31,415 unregistered shares of the Company's common stock totaling $5.4 million and contingent consideration with fair value of approximately $6.6 million.

Under the acquisition method of accounting, the assets acquired and liabilities assumed of FlexBiosys were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is $14.1 million, the fair value of the intangible assets acquired is $12.6 million and the residual goodwill is $14.3 million. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $1.1 million of transaction and integration costs associated with the FlexBiosys Acquisition from the date of acquisition to June 30, 2024. There were no transaction and integration costs incurred for the FlexBiosys Acquisition during the three and six months ended June 30, 2024.

Fair Value of Net Assets Acquired

The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the final valuation of FlexBiosys. The Company has made appropriate adjustments to purchase price allocation during the measurement period, which ended on April 17, 2024. The purchase price allocation was completed as of March 31, 2024.

The components and final allocation of the purchase price consist of the following (amounts in thousands):

Cash and cash equivalents |  | $ | 1,090 |
Accounts receivable |  |  | 683 |
Inventory |  |  | 667 |
Prepaid expenses and other current assets |  |  | 35 |
Property and equipment |  |  | 12,034 |
Operating lease right of use asset |  |  | 3,537 |
Customer relationships |  |  | 2,530 |
Developed technology |  |  | 9,860 |
Trademark and tradename |  |  | 30 |
Non-competition agreements |  |  | 220 |
Goodwill |  |  | 14,321 |
Other noncurrent assets |  |  | 10 |
Accounts payable |  |  | (136 | )
Accrued liabilities |  |  | (314 | )
Operating lease liability |  |  | (39 | )
Noncurrent operating lease liability |  |  | (3,498 | )
Fair value of net assets acquired |  | $ | 41,030 |

Acquired Goodwill

The goodwill of $14.3 million represents future economic benefits expected to arise from anticipated synergies from the integration of FlexBiosys into the Company. These synergies include operating efficiencies and strategic benefits projected to be achieved as a result of the FlexBiosys Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes.

Intangible Assets

The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives:

|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Customer relationships |  | 12 years |  | $ | 2,530 |
Developed technology |  | 16 years |  |  | 9,860 |
Trademark and tradename |  | 4 years |  |  | 30 |
Non-competition agreements |  | 5 years |  |  | 220 |
|  |  |  | $ | 12,640 |

5.
Restructuring Plan

In July 2023, the Board of Directors authorized the Company's management team to undertake restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. Since the initial streamlining and re-balancing efforts contemplated in July, the Company continues to undertake further restructuring activities (collectively, the “Restructuring Plan”) which has included consolidating a portion of our manufacturing operations between certain U.S. locations, discontinuing the sale of certain product SKUs, and evaluating the fair value of finished goods and raw materials, mostly secured

19

during the 2020-2022 COVID-19 pandemic period to meet increasing demand during a challenging supply chain environment in the industry.

The Company recorded pre-tax restructuring activity of $1.0 million and $2.4 million, respectively, for the three and six months ended June 30, 2024, related to the Restructuring Plan and expects the Restructuring Plan to be completed by the end of the third quarter of 2024.

The following table summarizes the charges related to restructuring activities by type of cost:

|  | For the Three Months Ended June 30, 2024 |
|  | Severance & Employee-Related Costs |  |  | Accelerated Depreciation |  |  | Facility and Other Exit Costs |  |  | Total |
|  | (Amounts in thousands) |
Cost of goods sold |  | $ | 371 |  |  | $ | — |  |  | $ | 143 |  |  | $ | 514 |
Research and development |  |  | 284 |  |  |  | — |  |  |  | — |  |  |  | 284 |
Selling, general and administrative |  |  | 157 |  |  |  | — |  |  |  | 17 |  |  |  | 174 |
|  | $ | 812 |  |  | $ | — |  |  | $ | 160 |  |  | $ | 972 |

|  | For the Six Months Ended June 30, 2024 |
|  | Severance & Employee-Related Costs |  |  | Accelerated Depreciation |  |  | Facility and Other Exit Costs |  |  | Total |
|  | (Amounts in thousands) |
Cost of goods sold |  | $ | 853 |  |  | $ | 19 |  |  | $ | 201 |  |  | $ | 1,073 |
Research and development |  |  | 449 |  |  |  | — |  |  |  | — |  |  |  | 449 |
Selling, general and administrative |  |  | 856 |  |  |  | — |  |  |  | 17 |  |  |  | 873 |
|  | $ | 2,158 |  |  | $ | 19 |  |  | $ | 218 |  |  | $ | 2,395 |

Severance and employee-related costs under the Restructuring Plan are primarily associated with actual headcount reductions. Costs incurred include cash severance and non-cash severance, including other termination benefits. Severance and other termination benefit packages are based on established benefit arrangements or local statutory requirements and we recognized the contractual component of these benefits when payment was probable and could be reasonably estimated.

Non-cash charges for accelerated depreciation were recognized on long-lived assets that were taken out of service before the end of their normal service due to the shutdown of manufacturing facilities and production lines, in which case depreciation estimates were revised to reflect the use of the assets over their shortened useful life.

The restructuring accrual is included in accrued liabilities in the condensed consolidated balance sheet as of June 30, 2024 and the balance is expected to be paid by the third quarter of 2024. Activity related to the Restructuring Plan for the six months ended June 30, 2024 was as follows (amounts in thousands):

|  | Restructuring Liability December 31, 2023 |  |  | Restructuring Costs |  |  | Amounts Paid in 2024 |  |  | Noncash Restructuring Items |  |  | Restructuring Liability June 30, 2024 |
Severance & employee-related costs |  | $ | 464 |  |  | $ | 2,158 |  |  | $ | (1,909 | ) |  | $ | (74 | ) |  | $ | 639 |
Accelerated depreciation |  |  | — |  |  |  | 19 |  |  |  | — |  |  |  | (19 | ) |  |  | — |
Facility and other exit costs |  |  | — |  |  |  | 218 |  |  |  | (218 | ) |  |  | — |  |  |  | — |
Total |  | $ | 464 |  |  | $ | 2,395 |  |  | $ | (2,127 | ) |  | $ | (93 | ) |  | $ | 639 |

6.
Revenue Recognition

Disaggregation of Revenue

Revenues for the three and six months ended June 30, 2024 and 2023 were as follows:

20

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (Amounts in thousands) |
|  | (As Restated) |  |  |  |  |  | (As Restated) |  |  | (As Restated) |
Product revenue |  | $ | 158,804 |  |  | $ | 159,133 |  |  | $ | 311,950 |  |  | $ | 324,474 |
Royalty and other income |  |  | 35 |  |  |  | 36 |  |  |  | 71 |  |  |  | 75 |
Total revenue |  | $ | 158,839 |  |  | $ | 159,169 |  |  | $ | 312,021 |  |  | $ | 324,549 |

When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory, economic and geopolitical developments within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows.

Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 15, “Segment Reporting,” included in this report.

For more information regarding our product revenue, see Note 8, “Revenue Recognition” included in Part II, Item 8, “Financial Statements and Supplementary Data” to the Company’s Form 10-K/A.

Contract Balances from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2024 and December 31, 2023 (amounts in thousands):

|  | June 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (As Restated) |  |  | (As Restated) |
Balances from contracts with customers only: |  |  |  |  |  |
Accounts receivable |  | $ | 123,245 |  |  | $ | 124,161 |
Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the condensed consolidated balance sheets) |  | $ | 14,461 |  |  | $ | 17,536 |
Revenue recognized during periods presented relating to: |  |  |  |  |  |
The beginning deferred revenue balance |  | $ | 13,420 |  |  | $ | 18,751 |

The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s condensed consolidated balance sheets.

7.
Goodwill and Intangible Assets (As Restated)

Goodwill

The following table represents the change in the carrying value of goodwill for the six months ended June 30, 2024 (amounts in thousands):

Balance at December 31, 2023 |  | $ | 987,120 |
Measurement period adjustment - Metenova |  |  | (56 | )
Cumulative translation adjustment |  |  | (1,451 | )
Balance at June 30, 2024 |  | $ | 985,613 |

The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three and six months ended June 30, 2024.

Intangible assets (As Restated)

Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented.

Intangible assets, net, consisted of the following at June 30, 2024:

21

|  | June 30, 2024 |
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |  |  | Weighted Average Useful Life (in years) |
|  | (Amounts in thousands) |  |  |  |
Finite-lived intangible assets: |  | (As Restated) |  |  | (As Restated) |  |  | (As Restated) |  |  |  |
Technology - developed |  | $ | 253,859 |  |  | $ | (52,503 | ) |  | $ | 201,356 |  |  |  | 16 |
Patents |  |  | 240 |  |  |  | (240 | ) |  |  | — |  |  |  | 8 |
Customer relationships |  |  | 268,683 |  |  |  | (92,419 | ) |  |  | 176,264 |  |  |  | 15 |
Trademarks |  |  | 8,698 |  |  |  | (2,043 | ) |  |  | 6,655 |  |  |  | 19 |
Other intangibles |  |  | 3,859 |  |  |  | (2,786 | ) |  |  | 1,073 |  |  |  | 3 |
Total finite-lived intangible assets |  |  | 535,339 |  |  |  | (149,991 | ) |  |  | 385,348 |  |  |  | 15 |
Indefinite-lived intangible asset: |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  |  | 700 |  |  |  | — |  |  |  | 700 |  |  |  | — |
Total intangible assets |  | $ | 536,039 |  |  | $ | (149,991 | ) |  | $ | 386,048 |  |  |  |

Intangible assets, net, consisted of the following at December 31, 2023:

|  | December 31, 2023 |
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |  |  | Weighted Average Useful Life (in years) |
|  | (Amounts in thousands) |  |  |  |
Finite-lived intangible assets: |  | (As Restated) |  |  | (As Restated) |  |  | (As Restated) |  |  |  |
Technology - developed |  | $ | 256,536 |  |  | $ | (44,633 | ) |  | $ | 211,903 |  |  |  | 16 |
Patents |  |  | 240 |  |  |  | (240 | ) |  |  | — |  |  |  | 8 |
Customer relationships |  |  | 269,949 |  |  |  | (83,963 | ) |  |  | 185,986 |  |  |  | 15 |
Trademarks |  |  | 8,757 |  |  |  | (1,789 | ) |  |  | 6,968 |  |  |  | 19 |
Other intangibles |  |  | 3,914 |  |  |  | (2,514 | ) |  |  | 1,400 |  |  |  | 3 |
Total finite-lived intangible assets |  |  | 539,396 |  |  |  | (133,139 | ) |  |  | 406,257 |  |  |  | 15 |
Indefinite-lived intangible asset: |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  |  | 700 |  |  |  | — |  |  |  | 700 |  |  |  | — |
Total intangible assets |  | $ | 540,096 |  |  | $ | (133,139 | ) |  | $ | 406,957 |  |  |  |

Amortization expense for finite-lived intangible assets was $8.7 million and $7.7 million for each of the three months ended June 30, 2024 and 2023, respectively, and $17.4 million and $15.1 million for each of the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the Company expects to record the following amortization expense in future periods (amounts in thousands):

|  | Estimated |
|  | Amortization |
|  | Expense |
For the Years Ended December 31, |  | (As Restated) |
2024 (remaining six months) |  | $ | 17,117 |
2025 |  |  | 34,079 |
2026 |  |  | 33,741 |
2027 |  |  | 33,707 |
2028 |  |  | 33,608 |
2029 and thereafter |  |  | 233,096 |
Total |  | $ | 385,348 |

8.
Consolidated Balance Sheet Detail

Inventories, net

Inventories, net consists of the following:

|  | June 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (Amounts in thousands) |
Raw materials |  | $ | 111,487 |  |  | $ | 123,598 |
Work-in-process |  |  | 5,248 |  |  |  | 4,492 |
Finished products |  |  | 73,793 |  |  |  | 74,231 |
Total inventories, net |  | $ | 190,528 |  |  | $ | 202,321 |

22

Assets held for sale

During the first quarter of 2024, the Company’s management decided it would explore a sale of the Company’s property located at 119 Fredon Springdale Road, Fredon, New Jersey (the “BioFlex Property”) and engaged a broker to assist with the sale process. As of June 30, 2024, the Company continues to conduct a sale process for the BioFlex Property, with the expectation of completing the sale by the end of 2024. As a result of these actions, the sale of the BioFlex Property meets the criteria to be classified as assets held-for-sale pursuant to ASC 360, “Impairment and Disposal of Long-Lived Assets.” Therefore, the Company recorded $1.0 million in assets held for sale in our condensed consolidated balance sheet as of June 30, 2024.

Assets held for sale as of June 30, 2024 (for which there were no comparable amounts as of December 31, 2023) consist of the following (amounts in thousands):

|  | June 30, |
|  | 2024 |
Land |  | $ | 101 |
Buildings |  |  | 915 |
Total assets held for sale |  | $ | 1,016 |

Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

|  | June 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (Amounts in thousands) |
Land |  | $ | 831 |  |  | $ | 992 |
Buildings |  |  | 697 |  |  |  | 1,667 |
Leasehold improvements |  |  | 128,455 |  |  |  | 126,663 |
Equipment |  |  | 114,013 |  |  |  | 114,606 |
Furniture, fixtures and office equipment |  |  | 9,046 |  |  |  | 9,077 |
Computer hardware and software |  |  | 39,942 |  |  |  | 35,528 |
Construction in progress |  |  | 54,334 |  |  |  | 47,086 |
Other |  |  | 501 |  |  |  | 544 |
Total property, plant and equipment |  |  | 347,819 |  |  |  | 336,163 |
Less - Accumulated depreciation |  |  | (143,220 | ) |  |  | (128,723 | )
Total property, plant and equipment, net |  | $ | 204,599 |  |  | $ | 207,440 |

Accrued liabilities

Accrued liabilities consist of the following:

|  | June 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (Amounts in thousands) |
|  | (As Restated) |  |  | (As Restated) |
Employee compensation |  | $ | 23,438 |  |  | $ | 16,660 |
Deferred revenue |  |  | 14,001 |  |  |  | 17,067 |
Income taxes payable |  |  | 1,071 |  |  |  | 6,814 |
Other |  |  | 19,839 |  |  |  | 16,772 |
Total accrued liabilities |  | $ | 58,349 |  |  | $ | 57,313 |

9.
Convertible Senior Notes

The carrying value of the Company's convertible senior notes is as follows:

23

|  | June 30, 2024 |  |  | December 31, 2023 |
|  | (Amounts in thousands) |
1.00% Convertible Senior Notes due 2028: |  |  |  |  |  |
Principal amount |  | $ | 600,000 |  |  | $ | 600,000 |
Unamortized debt discount |  |  | (74,733 | ) |  |  | (81,457 | )
Unamortized debt issuance costs |  |  | (7,542 | ) |  |  | (8,400 | )
Carrying amount - Convertible Senior Notes due 2028, net |  | $ | 517,725 |  |  | $ | 510,143 |
0.375% Convertible Senior Notes due 2024: |  |  |  |  |  |
Principal amount |  | $ | 69,504 |  |  | $ | 69,700 |
Unamortized debt issuance costs |  |  | (23 | ) |  |  | (248 | )
Carrying amount - Convertible Senior Notes due 2024, net |  | $ | 69,481 |  |  | $ | 69,452 |

1.00% Convertible Senior Notes due 2028

On December 14, 2023, the Company issued $600.0 million aggregate principal amount of its 2023 Notes in the Exchange and Subscription Agreements with a limited number of holders of its outstanding 2019 Notes and certain other qualified institutional buyers pursuant to Rule 144A under the Securities Act. Pursuant to the Exchange and Subscription Agreements and to the Exchange Transaction, the Company issued $290.1 million aggregate principal amount of the 2023 Notes in a private placement to accredited institutional buyers (the “Subscription Transactions”) for $290.1 million in cash.

The Company evaluated the Exchange Transaction and determined approximately $29.6 million of the $217.7 million principal of the exchanged 2019 Notes should be accounted for as extinguishments of debt and approximately $188.1 million should be accounted for as modification of debt. As a result, the Company recognized a $12.7 million loss on extinguishments of debt in its consolidated statements of comprehensive income (loss) for the year ended December 31, 2023, inclusive of $0.1 million of unamortized debt issuance costs. Under debt modification accounting, the carrying amount of the modified 2019 Notes was reduced by $2.8 million, with a corresponding increase to additional paid-in capital, to account for the increase in the fair value of the embedded conversion option, representing a debt discount of the modified 2019 Notes. The aggregate debt discount of $74.7 million as of June 30, 2024, comprised of $72.2 million increase in principal of the modified 2019 Notes and a $2.5 million increase in the fair value of the embedded conversion option. The aggregate debt discount of $81.5 million as of December 31, 2023, comprised of $78.7 million increase in principal of the modified 2019 Notes and a $2.8 million increase in the fair value of the embedded conversion option. These amounts are presented as a direct reduction from the carrying value of the convertible debt in their respective periods presented in our condensed consolidated balance sheets. This amount is being accreted into interest expense in the condensed consolidated statements of comprehensive income (loss) using the effective interest method over the term of the 2023 Notes.

Proceeds from the Subscription Transactions were $276.1 million, net of debt issuance costs of $13.9 million. The Exchange Transaction resulted in $6.2 million of the debt issuance costs related to the modified 2019 Notes, which were expensed as incurred in accordance with debt modification accounting, and $7.7 million of deferred debt issuance costs related to the 2023 Notes, which were recorded as a direct deduction to the carrying value of the 2023 Notes on the Company’s condensed consolidated balance sheets. The Company is amortizing the $7.7 million of debt issuance costs of the 2023 Notes into amortization of debt issuance costs in the Company’s condensed consolidated statements of comprehensive income (loss) over the remaining term of the 2023 Notes. The carrying value of the 2023 Notes of $517.7 million and $510.1 million is included in long-term debt on the Company's condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively.

The Company used $14.4 million of the proceeds from the Subscription Transactions to repurchase shares of its common stock from certain purchasers of the 2023 Notes. For more information regarding this repurchase, see Note 13, “Stockholders’ Equity - Share Repurchases” included in Part II, Item 8, “Financial Statements and Supplementary Data,” to the Company's Form 10-K/A. The Company will also use a portion of the proceeds to finance in part, the settlement upon conversion or repurchase of the remaining 2019 Notes at maturity. See Note 16, “Subsequent Events - Maturity of the Remaining 2019 Notes” below for more information on the redemption of the 2019 Notes. The remainder of the proceeds will be used for working capital.

The 2023 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 1.00% per year. Interest is payable semi-annually in arrears on each of June 15 and December 15, which commenced on June 15, 2024. The 2023 Notes will mature on December 15, 2028, unless earlier redeemed, repurchased or converted. During the second quarter of 2024, the closing price of the Company’s common stock did not exceed 130% of the conversion price of the 2023 Notes for more than 20 trading days of the last 30 consecutive trading of the quarter. As a result, the 2023 Notes are not convertible at the option of the holders of the 2023 Notes during the third quarter of 2024, the quarter immediately following the quarter when the conditions are met, as

24

stated in the indenture governing the 2023 Notes. Because the 2023 Notes were not convertible as of June 30, 2024, the Company classifies the carrying value of the 2023 Notes of $517.7 million as noncurrent liabilities on the Company’s condensed consolidated balance sheet at June 30, 2024. The initial conversion rate for the 2023 Notes is 4.9247 shares of the Company’s common stock per $1,000 principal amount of 2023 Notes, which is equivalent to an initial conversion price of $203.06 per share and represents a 30% premium over the last reported sale price of $156.20 per share on December 6, 2023, the date on which the 2023 Notes were priced. Prior to the close of business on the business day immediately preceding September 15, 2028, the 2023 Notes will be convertible at the option of the holders of 2023 Notes only upon the satisfaction of the specified conditions mentioned above and during certain quarters commencing after the calendar quarter ending on March 31, 2024, into cash up to their principal amount, and into cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, for the conversion value above the principal amount, if any. Thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2023 Notes will be convertible at the option of the holders of 2023 Notes at any time regardless of these conditions. The Company may redeem for cash, all or a portion of the 2023 Notes, at its option, on or after December 18, 2026 and prior to the 21 st scheduled trading day immediately preceding the maturity date at a redemption price of 100% of the principal amount of the 2023 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date, if certain conditions are met in accordance to the 2023 Notes Indenture. For more information on the 2023 Notes, see Note 15, “Convertible Senior Notes,” included in Part II, Item 8, “Financial Statements and Supplementary Data,” to the Company’s Form 10-K/A.

The following table sets forth total interest expense recognized related to the 2023 Notes for the three and six months ended June 30, 2024 for which there were no comparable amounts for the same periods of 2023:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2024 |
|  | (Amounts in thousands, except percentage data) |
Contractual interest expense – 2023 Notes |  | $ | 1,500 |  |  | $ | 3,000 |
Amortization of debt discount – 2023 Notes |  |  | 3,398 |  |  |  | 6,724 |
Amortization of debt issuance costs – 2023 Notes |  |  | 408 |  |  |  | 815 |
Total |  | $ | 5,306 |  |  | $ | 10,539 |
Effective interest rate of the liability component |  |  | 4.39 | % |  |  | 4.39 | %

At June 30, 2024 and December 31, 2023, the carrying value of the 2023 Notes was $517.7 million and $510.1 million, respectively, net of unamortized discount, and the fair value of the 2023 Notes was $497.4 million and $596.0 million, respectively. The fair value of the 2023 Notes was determined based on the most recent trade activity of the 2023 Notes at June 30, 2024 and December 31, 2023.

0.375% Convertible Senior Notes due 2024

The Company issued $287.5 million aggregate principal amount of the 2019 Notes on July 19, 2019 in a transaction which included the underwriters’ exercise in full of an option to purchase an additional $37.5 million aggregate principal amount of the 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $278.5 million. Immediately following the closing of the Exchange Transaction mentioned above, $69.7 million in aggregate principal amount of the 2019 Notes remained outstanding as of December 31, 2023. As of June 30, 2024, subsequent to the conversion of another $0.2 million, $69.5 million in aggregate principal amount remains outstanding.

The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375% per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The remaining 2019 Notes matured on July 15, 2024. The initial conversion rate for the 2019 Notes is 8.6749 shares of the Company’s common stock per $1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $115.28 per share). The 2019 Notes are convertible as of June 30, 2024 at the option of the holders at any time regardless of prior conditions that were in place and were convertible until the close of business on July 11, 2024, the second scheduled trading day immediately preceding the maturity date. The 2019 Notes are not redeemable by the Company prior to maturity. See Note 16, “Subsequent Event - Maturity of the Remaining 2019 Notes” below for more information on the July 15, 2024 maturity.

As of the date of this filing, excluding the Exchange Transaction mentioned above, the Company has received requests to convert $0.3 million aggregate principal amount of the 2019 Notes and all have been settled as of June 30, 2024. These conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. Because the 2019

25

Notes matured in July 2024, the Company classified the carrying value of the 2019 Notes as current liabilities on the Company’s condensed consolidated balance sheets at June 30, 2024.

The following table sets forth total interest expense recognized related to the 2019 Notes:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (Amounts in thousands, except percentage data) |
Contractual interest expense – 2019 Notes |  | $ | 65 |  |  | $ | 269 |  |  | $ | 130 |  |  | $ | 539 |
Amortization of debt issuance costs – 2019 Notes |  |  | 112 |  |  |  | 457 |  |  |  | 224 |  |  |  | 914 |
Total |  | $ | 177 |  |  | $ | 726 |  |  | $ | 354 |  |  | $ | 1,453 |
Effective interest rate of the liability component |  |  | 1.00 | % |  |  | 1.00 | % |  |  | 1.00 | % |  |  | 1.00 | %

At June 30, 2024 and December 31, 2023, the carrying value of the 2019 Notes was $69.5 million, respectively, net of unamortized discount, and the fair value of the 2019 Notes was $82.6 million and $109.8 million, respectively. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes at June 30, 2024 and December 31, 2023.

10.
Stockholders’ Equity

Stock Option and Incentive Plans

Under the Company’s current 2018 Stock Option and Incentive Plan (the “2018 Plan”), the number of shares of the Company’s common stock that were reserved and available for issuance is 2,778,000, plus the number of shares of common stock that were available for issuance under the Company’s previous equity plans. The shares of common stock underlying any awards under the 2018 Plan and previous equity plans (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At June 30, 2024, 1,523,889 shares were available for future grants under the 2018 Plan.

Chief Executive Officer Accounting Modifications (As Restated)

On June 12, 2024, upon approval by the Board, the Company entered into the Fourth Amended and Restated Employment Agreement (the “Transition Agreement”) with the Company's Chief Executive Officer (“CEO”), Tony J. Hunt, which amends and restates Mr. Hunt's Third Amended and Restated Employment Agreement with the Company dated as of May 26, 2022. Under the terms of the Transition Agreement, Mr. Hunt will relinquish his position as the Company's CEO effective September 1, 2024 (the “Transition Date”) and will transition to a new role as Executive Chair of the Board beginning on the Transition Date (the “CEO Transition”). It is anticipated that Mr. Hunt will continue to be involved in the business as the Executive Chair of the Board until March 2026 and will continue to be employed by the Company as an advisor thereafter, until March 2027.

Under the terms of the Transition Agreement and the award agreements governing Mr. Hunt’s outstanding equity awards, Mr. Hunt’s unvested stock awards will continue to vest in accordance with their original terms. Furthermore, on June 28, 2024, the Company entered into an amendment (the “2024 Award Amendment”) to the equity awards granted to Mr. Hunt in 2024, which consisted of a stock option, restricted stock units (“RSUs”) and performance stock units (“PSUs” and together the “2024 Grants”). Pursuant to the terms of the 2024 Award Amendment, two-thirds of the 2024 Grants were forfeited, which equates to 32,776 shares of the Company’s common stock.

Although Mr. Hunt’s unvested equity awards continue to vest in accordance with their original terms and there has been no amendment to Mr. Hunt’s outstanding equity awards other than the 2024 Award Amendment, the Company determined that under ASC 718, ”Compensation - Stock Compensation”, the CEO Transition represents a significant reduction in Mr. Hunt’s operating role with the Company for accounting purposes. This determination resulted in a Type III accounting modification of certain of Mr. Hunt’s unvested stock awards (improbable to probable) under ASC 718 (the “Equity Modification”) on June 12, 2024. As a result, for accounting purposes only, Mr. Hunt’s unvested awards were deemed cancelled and a new grant issued for his unvested shares with the value of these awards recalculated using a price of $136.00 per share, which was the opening stock price of the first day of trading following the public announcement of the CEO Transition.

26

As a result of the Equity Modification, the Company will recognize stock-based compensation expense for the modified awards of $22.4 million over the remaining requisite service period, which the Company determined to be between June 13, 2024 and September 1, 2024 and represents the remaining service period of Mr. Hunt’s role as CEO.

The Company determined that the PSUs granted to Mr. Hunt in 2022 and 2023 should be accounted for as a Type IV accounting modification (improbable to improbable) in accordance with ASC 718, because vesting conditions before and after June 12, 2024 were improbable of being achieved.

As a result of the Equity Modification and the forfeiture of the pro-rata portion of Mr. Hunt’s 2024 Grants, the Company recognized $5.0 million of incremental stock-based compensation expense for the three and six months ended June 30, 2024.

Stock Issued for Earnout Payments

In April 2024, the Company issued 28,638 shares of its common stock to former securityholders of Avitide to satisfy the contingent consideration obligation established under the Agreement and Plan of Merger and Reorganization (the “Avitide Agreement”) which the Company entered into as part of the acquisition of Avitide in September 2021.

In March 2024, the Company issued 2,770 shares of its common stock to former securityholders of FlexBiosys to satisfy the contingent consideration obligation established under the FlexBiosys Agreement, which the Company entered into as part of the acquisition of FlexBiosys in April 2023.

See Note 5, “Acquisitions”, included in Part II, Item 8, “Financial Statements and Supplementary Data,” to the Company’s Form 10-K/A for additional information on the acquisitions of Avitide and FlexBiosys and the contingent consideration. The shares issued to FlexBiosys represent 20% of the earnout consideration earned in the First Earnout Year (as defined in the FlexBiosys Agreement) and the shares issued to Avitide represents 50% of the earnout consideration earned in the Second Earnout Year (as defined in the Avitide Agreement).

Stock-Based Compensation

The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income (loss):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (Amounts in thousands) |
|  | (As Restated) |  |  |  |  |  | (As Restated) |  |  |  |
Cost of goods sold |  | $ | 498 |  |  | $ | 522 |  |  | $ | 1,102 |  |  | $ | 1,113 |
Research and development |  |  | 503 |  |  |  | 608 |  |  |  | 1,447 |  |  |  | 1,395 |
Selling, general and administrative(1) |  |  | 8,878 |  |  |  | 4,353 |  |  |  | 16,106 |  |  |  | 10,229 |
Total stock-based compensation |  | $ | 9,879 |  |  | $ | 5,483 |  |  | $ | 18,655 |  |  | $ | 12,737 |

(1)
Selling, general and administrative stock-based compensation for the three and six months ended June 30, 2024 includes $5.0 million of expense related to the Equity Modification discussed above.

Stock Options

Information regarding option activity for the six months ended June 30, 2024 under the Plans is summarized below:

|  | Shares |  |  | Weighted average exercise price |  |  | Weighted- Average Remaining Contractual Term (in Years) |  |  | Aggregate Intrinsic Value (in Thousands) |
Options outstanding at December 31, 2023 |  |  | 649,130 |  |  | $ | 85.97 |  |  |  |  |  |  |
Granted |  |  | 60,736 |  |  | $ | 184.66 |  |  |  |  |  |  |
Exercised |  |  | (26,661 | ) |  | $ | 67.08 |  |  |  |  |  |  |
Forfeited/expired/cancelled(1) |  |  | (22,027 | ) |  | $ | 192.07 |  |  |  |  |  |  |
Options outstanding at June 30, 2024 |  |  | 661,178 |  |  | $ | 92.26 |  |  |  |  |  |  |
Options exercisable at June 30, 2024 |  |  | 413,411 |  |  | $ | 74.55 |  |  |  |  |  |  |
Vested and expected to vest at June 30, 2024(2) |  |  | 655,251 |  |  | $ | 91.51 |  |  |  | 5.41 |  |  | $ | 35,463 |

27

(1)
Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications”.
(2)
Represents the number of vested options as of June 30, 2024 plus the number of unvested options expected to vest as of June 30, 2024 based on the unvested outstanding options at June 30, 2024 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on June 28, 2024, the last business day of the second quarter of 2024, of $126.06 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on June 30, 2024. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2024 and 2023 was $2.6 million and $0.7 million, respectively.

The weighted average grant date fair value of options granted during the six months ended June 30, 2024 and 2023 was $93.65 and $86.30, respectively.

Stock Units

The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the six months ended June 30, 2024 under the Plans is summarized below:

|  | Shares |  |  | Weighted Average Grant Date Fair Value |  |
Unvested at December 31, 2023 |  |  | 474,320 |  |  | $ | 155.59 |  |
Awarded |  |  | 178,252 |  |  | $ | 188.57 |  |
Vested |  |  | (125,820 | ) |  | $ | 143.87 |  |
Forfeited/cancelled(1) |  |  | (69,442 | ) |  | $ | 189.15 |  |
Unvested at June 30, 2024 |  |  | 457,310 |  |  | $ | 166.59 |  |
Vested and expected to vest at June 30, 2024(2) |  |  | 397,312 |  |  | $ | 164.77 |  |

(1)
Includes 13,146 RSUs and 6,573 PSUs forfeited pursuant to the 2024 Award Amendment discussed above under ”Chief Executive Officer Accounting Modifications”.
(2)
Represents the number of vested stock units as of June 30, 2024 plus the number of unvested stock units expected to vest as of June 30, 2024 based on the unvested outstanding stock units at June 30, 2024 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value of stock units vested during the six months ended June 30, 2024 and 2023 was $23.5 million and $29.6 million, respectively.

The weighted average grant date fair value of stock units granted during the six months ended June 30, 2024 and 2023 was $188.57 and $176.86, respectively.

As of June 30, 2024, there was $73.3 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 2.59 years. The Company expects 2,267,696 unvested options and stock units to vest over the next five years.

11.
Commitments and Contingencies

Collaboration Agreements

The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements that require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three and six months ended June 30, 2024 and 2023.

In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which the Company holds commercialization rights. The Company is manufacturing and supplying

28

the first of these ligands, NGL-Impact®, exclusively to Purolite Life Sciences, an Ecolab Inc. company (“Purolite”), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, that was used in the purification of vaccines for the COVID-19 pandemic, including emerging variants of the SARS-CoV-2 coronavirus. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact® HipH, to Purolite. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $0.9 million and $1.2 million for the three months ended June 30, 2024 and 2023, respectively, and payments of $1.7 million and $2.3 million for the six months ended June 30, 2024 and 2023, respectively.

Legal Proceedings

From time to time, in the normal course of its operations, the Company is subject to litigation matters and claims relating to employee relations, business practices and patent infringement. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict, and the Company's view of these matters may change in the future as the litigation and events related thereto unfold. The Company expenses legal fees as incurred. The Company records a provision for contingent losses when it is both probably that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial results.

12.
Income Taxes (As Restated)

For the three and six months ended June 30, 2024, the Company recorded an income tax provision of $3.3 million and $3.7 million, respectively. The Company’s effective tax rate for the three and six months ended June 30, 2024 was 36.7% and 29.2%, respectively, compared to 20.6% and 19.2% for the corresponding periods in the prior year.

In 2021, the Organization of Economic Co-operation and Development announced an Inclusive Framework on Base Erosion and Profit Sharing with the goal of achieving consensus around substantial changes to international tax policies, including the implementation of a minimum global effective tax rate of 15%. The Company continues to evaluate the impacts of enacted legislation and pending legislation in the tax jurisdictions in which the Company operates. While various countries have implemented the legislature as of January 1, 2024, the Company does not expect a resulting material impact to its income tax provision for the 2024 fiscal year.

13.
Earnings Per Share

29

A reconciliation of basic and diluted weighted average shares outstanding is as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (Amounts in thousands, except per share data) |
Numerator: |  | (As Restated) |  |  | (As Restated) |  |  | (As Restated) |  |  | (As Restated) |
Net income |  | $ | 5,713 |  |  | $ | 19,786 |  |  | $ | 9,009 |  |  | $ | 35,123 |
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares used in computing net income per share - basic |  |  | 55,884 |  |  |  | 55,705 |  |  |  | 55,838 |  |  |  | 55,648 |
Effect of dilutive shares: |  |  |  |  |  |  |  |  |  |  |  |
Options and stock units |  |  | 391 |  |  |  | 451 |  |  |  | 437 |  |  |  | 487 |
Convertible senior notes(1) |  |  | 159 |  |  |  | 701 |  |  |  | 202 |  |  |  | 797 |
Dilutive effect of unvested performance stock units |  |  | — |  |  |  | 1 |  |  |  | — |  |  |  | — |
Dilutive potential common shares |  |  | 550 |  |  |  | 1,153 |  |  |  | 639 |  |  |  | 1,284 |
Denominator for diluted earnings per share - adjusted weighted average shares used in computing earnings per share - diluted |  |  | 56,434 |  |  |  | 56,858 |  |  |  | 56,477 |  |  |  | 56,932 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.10 |  |  | $ | 0.36 |  |  | $ | 0.16 |  |  | $ | 0.63 |
Diluted |  | $ | 0.10 |  |  | $ | 0.35 |  |  | $ | 0.16 |  |  | $ | 0.62 |

(1)
Represents the dilutive impact for the Company's 2019 Notes. As of June 30, 2024, the if-converted value is less than the outstanding principal of the 2023 Notes and are therefore anti-dilutive. Refer to Note 9, "Convertible Senior Notes," above for more information.

For the three and six months ended June 30, 2024, 479,482 sh ares and 358,633 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. Comparatively, for the three and six months ended June 30, 2023, 456,315 shares and 400,909 shares, respectively, were considered anti-dilutive.

In July 2019, the Company issued $287.5 million aggregate principal amount of its 2019 Notes. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, upon conversion of the 2019 Notes, the Company will use a combination of cash and shares of the Company's common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. On December 14, 2023, the Company exchanged, in a privately negotiated exchange, $309.9 million principal amount of 2023 Notes for $217.7 million principal amount of 2019 Notes and issued $290.1 million aggregate principal amount of 2023 Notes for $290.1 million in cash. Immediately following the closing of the Exchange Transaction mentioned above, $69.7 million in aggregate principal amount of the 2019 Notes remained outstanding as of December 31, 2023 with terms unchanged. As of June 30, 2024, subsequent to the conversion of another $0.2 million, $69.5 million in aggregate principal amount remains outstanding.

As mentioned above and as provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company’s common stock. This means the Company will settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company is required to reflect the dilutive effect of the convertible securities by application of the “if-converted” method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted earnings per share, but the dilutive effect of the conversion premium was considered in the calculation of diluted earnings per share using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there was a premium. For the three and six months ended June 30, 2024, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 159,494 shares and 201,917 shares, respectively. For the three and six months ended June 30, 2023, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 700,941 shares and 796,601 shares, respectively.

14.
Related Party Transactions

Certain facilities leased by our subsidiary, Spectrum LifeSciences LLC (“Spectrum”) are owned by the Roy Eddleman Living Trust (the “Trust”). As of June 30, 2024, the Trust owned greater than 5% of the Company’s outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust were negotiated in connection with the

30

acquisition of Spectrum. The Company incurred rent expense totaling $0.2 million for each of the three months ended June 30, 2024 and 2023 related to these leases and incurred $0.4 million for each of the six months ended June 30, 2024 and 2023.

15.
Segment Reporting

Operating segments are components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the CODM in deciding how to allocate resources and assess performance. Our CEO has been identified as the CODM.

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment and one reportable segment. Our CODM evaluates financial information on a consolidated basis. As a result, the required financial segment information can be found in the condensed consolidated financial statements of the Company disclosed herein.

The following table represents the Company’s total revenue by customers’ geographic locations:

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (As Restated) |  |  |  |  |  | (As Restated) |  |  | (As Restated) |
Revenue by customers' geographic locations: |  |  |  |  |  |  |  |  |  |  |  |
North America |  |  | 49 | % |  |  | 46 | % |  |  | 49 | % |  |  | 44 | %
Europe |  |  | 38 | % |  |  | 36 | % |  |  | 36 | % |  |  | 34 | %
APAC/Other |  |  | 13 | % |  |  | 18 | % |  |  | 15 | % |  |  | 22 | %
Total revenue |  |  | 100 | % |  |  | 100 | % |  |  | 100 | % |  |  | 100 | %

Concentrations of Credit Risk and Significant Customers (As Restated)

Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings, and credit exposure to any one issue, issuer (with the exception of U.S. Treasury obligations) and type of instrument is limited. At June 30, 2024 and December 31, 2023, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.

Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.

There was no revenue from customers that represented 10% or more of the Company's total revenue for the three and six months ended June 30, 2024 and 2023.

Significant accounts receivable balances representing 10% or more of the Company’s total trade accounts receivable balances at June 30, 2024 came from our accounts receivable balance outstanding with Novo Nordisk A/S, which was 11.6% of the Company’s total trade accounts receivable balance. No accounts receivable balance from a specific customer represented 10% or more of the Company's total trade accounts receivable at December 31, 2023.

16.
Subsequent Events

Maturity of the Remaining 2019 Notes

As discussed in Note 9, “Convertible Senior Notes” above, the remaining 2019 Notes matured and were paid off in full on July 15, 2024. The Company used net proceeds from the Exchange Transaction to fund the repayment of the 2019 Notes at maturity and to pay accrued and unpaid interest with respect to such notes. The Company irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and the Company’s common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. In connection with the conversion, the Company paid $69.6 million in cash, which included principal and accrued interest, and issued 100,942 shares of the Company’s common stock representing the conversion premium.

Pending Acquisition of Tantti Laboratory Inc.

31

On July 29, 2024, the Company announced that it entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”). Tantti, which is headquartered in Taoyuan City, Taiwan, is expected to accelerate the Company’s expansion into new modality markets with unique, scalable purification solutions for large molecule biologics.

The Company expects the acquisition of Tantti to be completed in the fourth quarter of 2024 subject to the satisfaction of customary closing conditions, including clearance through the Taiwanese regulatory channel.

32

ITEM 2. MANAGEMENT’S DISCUSSION AND ANAL YSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Repligen and its subsidiaries, collectively doing business as Repligen Corporation (“Repligen”, “we”, “our”, or the “Company”) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

As the overall market for biologics continues to grow and expand, our customers – primarily large biopharmaceutical companies and contract development and manufacturing organizations and other life sciences companies (integrators) – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products help set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies – that are improving human health worldwide. Increasingly, our technologies are being implemented to overcome challenges in processing plasmid DNA (a starting material for the production of mRNA) and gene delivery vectors such as lentivirus and adeno-associated viral vectors. For more information regarding our business, products and acquisitions, see Part I, Item 1, “Business”, included in our 2023 Annual Report on Form 10-K, as amended, which was filed with the Securities and Exchange Commission (“SEC”) on November 18, 2024 (“Form 10-K/A”).

We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug manufacturing. Building on over 40 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our passion for innovation and the customer-first culture that drives our entire organization. We continue to capitalize on opportunities to maximize the value of our product platform through both organic growth initiatives (internal innovation and leveraging commercial opportunities) and targeted acquisitions.

Restatement

As previously described in the Explanatory Note above and in Note 1 to our unaudited condensed consolidated financial statements, we have restated our previously issued unaudited condensed consolidated financial statements and related notes as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023. As a result, the previously reported financial information as of and for the three and six months ended June 30, 2024 and 2023 in this Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations has been updated to reflect the relevant restatement. Refer to Note 1 in our unaudited condensed consolidated financial statements for additional information related to the restatement, including descriptions of the adjustments and the impacts on our unaudited condensed consolidated financial statements.

Other than the effect of the restatement as described in Note 1 in our unaudited condensed consolidated financial statements, this section has not been otherwise modified and does not reflect any information or events occurring after July 30, 2024, the filing date of the Original Report, or modify or update those disclosures affected by events that occurred at a later date or facts that subsequently became known to the Company, except to the extent they are otherwise required to be included and discussed herein.

Macroeconomic Trends

As a result of our global presence, a significant portion of our revenue and expenses is denominated in currencies other than the U.S. dollar. We are therefore subject to non-U.S. exchange exposure. Exchange rates can be volatile and a substantial weakening or strengthening of foreign currencies against the U.S. dollar could increase or reduce our revenue and gross profit margin and impact the comparability of results from period to period.

We have experienced, and expect to continue to experience, cost inflation, primarily in raw materials, and other supply chain costs, as a result of global macroeconomic trends, including global geopolitical conflicts and labor shortages. Actions taken to mitigate supply chain disruptions and inflation, including price increases and productivity improvements, have generally been successful in offsetting the impact of these trends. In addition, decreasing demand for vaccines for the COVID-19 pandemic,

33

including all subsequent variants of the SARS-CoV-1 coronavirus is driving a reduction in future demand of our products related to these vaccines.

2024 Acquisition

Pending Acquisition of Tantti Laboratory Inc.

On July 29, 2024, we announced that we entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”). Tantti, which is headquartered in Taoyuan City, Taiwan, is expected to accelerate our expansion into new modality markets with unique, scalable purification solutions for large molecule biologics.

We expect the acquisition of Tantti to be completed in the fourth quarter of 2024 subject to the satisfaction of customary closing conditions, including clearance through the Taiwanese regulatory channel.

2023 Acquisitions

Acquisition of FlexBiosys, Inc.

On April 17, 2023, we completed the acquisition of all of the outstanding equity interests in FlexBiosys, Inc. (“FlexBiosys”), pursuant to an Equity Purchase Agreement with FlexBiosys, TSAP Holdings Inc. (“NJ Seller”), Gayle Tarry and Stanley Tarry, as individuals (collectively with NJ Seller, the “Sellers”), and Stanley Tarry, in his capacity as the representative of the Sellers (the “FlexBiosys Acquisition”).

FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies. These products will complement and expand our fluid management portfolio of offerings.

Acquisition of Metenova Holding AB

On October 2, 2023, we completed the acquisition of all of the outstanding equity interests in Metenova Holding AB (“Metenova”), pursuant to a Share Sale and Purchase Agreement with, inter alia, Metenova for approximately $173 million in cash and the Company's equity. Metenova will further strengthen our fluid management portfolio with its magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations.

Critical Accounting Policies and Estimates

A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a description of our critical accounting policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations and our significant accounting policies in Note 3, “Summary of Significant Accounting Policies”, to the consolidated financial statements included in our Form 10-K/A.

Results of Operations

The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and the related footnotes thereto.

34

Revenues (As Restated)

Total revenue for the three and six months ended June 30, 2024 and 2023 were as follows:

|  | Three Months Ended June 30, |  |  | Increase/(Decrease) |  |  | Six Months Ended June 30, |  |  | Increase/(Decrease) |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |  |  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
|  | (Amounts in thousands, except for percentage data) |
|  | (As Restated) |  |  |  |  |  |  |  |  |  |  |  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Products |  | $ | 158,804 |  |  | $ | 159,133 |  |  | $ | (329 | ) |  |  | (0.2 | %) |  | $ | 311,950 |  |  | $ | 324,474 |  |  | $ | (12,524 | ) |  |  | (3.9 | %)
Royalty and other |  |  | 35 |  |  |  | 36 |  |  |  | (1 | ) |  |  | (2.8 | %) |  |  | 71 |  |  |  | 75 |  |  |  | (4 | ) |  |  | (5.3 | %)
Total revenue |  | $ | 158,839 |  |  | $ | 159,169 |  |  | $ | (330 | ) |  |  | (0.2 | %) |  | $ | 312,021 |  |  | $ | 324,549 |  |  | $ | (12,528 | ) |  |  | (3.9 | %)

Product revenues (As Restated)

We focus on selling our products directly to customers in the pharmaceutical industry and to our contract manufacturers. These direct sales represented approximately 88.8% and 84.7% of our product revenue for each of the three months ended June 30, 2024 and 2023, respectively, and represented 89.6% and 83.6% of our product revenue for each of the six months ended June 30, 2024 and 2023. Sales of our bioprocessing products can be impacted by the timing of large-scale production orders and the regulatory approvals for such antibodies, which may result in significant quarterly fluctuations.

During the three and six months ended June 30, 2024, product revenue decreased by $0.3 million, or 0.2%, and $12.5 million, or 3.9%, respectively, as compared to the same periods of 2023. The decrease between the three and six-month periods is mainly due to a decrease in revenue from our proteins franchise due to weak demand, which reflects the Cytiva (a standalone operating company owned by Danaher Corporation) drop-off since they are producing product in-house and lower forecast for ligands from other customers. The decrease in revenue during the six-month periods also included a decrease in revenue from programs related to the COVID-19 pandemic as customers’ inventory has reduced at a slower pace than initially expected, which has primarily affected revenue from sales of our filtration products. Partially offsetting the decrease in revenue for the three and six month periods is an increase in revenue from the operations of acquisitions completed subsequent to the prior year comparable periods. In addition, the performance of our Alternating Tangential Filtration business, a part of our filtration franchise, was strong in the second quarter of 2024 as well as the first half of 2024 resulting in an increase in revenue during the three and six months ending June 30, 2024, as compared to the same periods of 2023. Revenue from sales by the remaining franchises for the three and six months ended June 30, 2024 remained relatively in line with similar revenue from the same periods of 2023.

Royalty and other revenues

Royalty and other revenues in the three and six months ended June 30, 2024 and 2023 relate to royalties received from a third-party systems manufacturer associated with our OPUS® chromatography columns. Royalty revenues are variable and are dependent on sales generated by our partners.

Costs of goods sold and operating expenses

Total costs and operating expenses for the three and six months ended June 30, 2024 and 2023 were comprised of the following:

|  | Three Months Ended June 30, | Increase/(Decrease) |  |  | Six Months Ended June 30, | Increase/(Decrease) |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |  |  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
|  | (Amounts in thousands, except for percentage data) |
|  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |  |  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |
Cost of goods sold |  | $ | 77,314 |  |  | $ | 79,307 |  |  | $ | (1,993 | ) |  |  | (2.5 | %) |  | $ | 153,705 |  |  | $ | 161,152 |  |  | $ | (7,447 | ) |  |  | (4.6 | %)
Research and development |  |  | 10,575 |  |  |  | 9,706 |  |  |  | 869 |  |  |  | 9.0 | % |  |  | 21,813 |  |  |  | 21,860 |  |  |  | (47 | ) |  |  | (0.2 | %)
Selling, general and administrative |  |  | 65,481 |  |  |  | 49,084 |  |  |  | 16,397 |  |  |  | 33.4 | % |  |  | 127,284 |  |  |  | 105,372 |  |  |  | 21,912 |  |  |  | 20.8 | %
Contingent Consideration |  |  | — |  |  |  | 1,791 |  |  |  | (1,791 | ) |  |  | (100.0 | %)) |  |  | — |  |  |  | 3,026 |  |  |  | (3,026 | ) |  |  | (100.0 | %)
Total costs and operating expenses |  | $ | 153,370 |  |  | $ | 139,888 |  |  | $ | 13,482 |  |  |  | 9.6 | % |  | $ | 302,802 |  |  | $ | 291,410 |  |  | $ | 11,392 |  |  |  | 3.9 | %

35

Cost of goods sold (As Restated)

Cost of goods sold decreased $2.0 million, or 2.5%, and $7.4 million, or 4.6% for the three and six months ended June 30, 2024, compared to the same periods of 2023, primarily due to a decrease in costs associated with lower revenue as well as a decrease in employee-related costs resulting from a decline in manufacturing headcount since June 30, 2023. Partially offsetting this was an increase in cost of goods sold that relates to the results of operations of FlexBiosys and Metenova, which have been in our consolidated results of operations since the acquisition dates in April 2023 and October 2023, respectively. There was also an increase in cost of goods sold during the three and six months ended June 30, 2024, as compared to the same periods of 2023 due to $0.5 million and $1.1 million, respectively, of costs incurred in 2024 from restructuring activities, for which there were no comparable costs in the same periods of 2023.

Gross margin was 51.3% and 50.2% in the three months ended June 30, 2024 and 2023, respectively and gross margin was 50.7% and 50.3% in the six months ended June 30, 2024 and 2023, respectively. Lower margins were a result of lower overall sales and production volumes, and a change in product mix, where we saw a significant decline in revenue associated with higher-margin consumable products due to the decrease in COVID-19 vaccine demand.

Research and development expenses

Research and development (“R&D”) expenses are related to bioprocessing products, which include personnel, supplies and other research expenses. Due to the fact that these various programs share personnel and fixed costs, we do not track all of our expenses or allocate any fixed costs by program, and therefore, have not provided historical costs incurred by project.

R&D expenses increased $0.9 million, or 9.0%, during the three months ended June 30, 2024, compared to the same period of 2023. The increase is primarily due to an adjustment to decrease the bonus accrual recorded during the second quarter of 2023 for which there is no comparable amount recorded in the same period of 2024. The increase is also attributable to the operations of Metenova, which have been in our results of operations since the acquisition date in October 2023 and $0.3 million of costs from restructuring activities during the three months ended June 30, 2024, for which there were no comparable costs in the same period of 2023. Offsetting these increases were decreases in employee-related costs from a decrease in headcount since June 30, 2023 and a decrease in spending on new product development during the three months ended June 30, 2024.

R&D expenses remained relatively consistent for the six months ended June 30, 2024, as compared to the same period of 2023 as the decreases in employee-related costs from lower R&D headcount as well as decreased spending on new product development during the first half of 2024, compared to the first half of 2023, were almost fully offset by the increase in R&D expenses that relate to the results of operations of FlexBiosys and Metenova. These results of operations have been in the consolidated results of operations since the acquisition dates in April 2023 and October 2023, respectively. There were also $0.4 million of costs from restructuring activities incurred by the Company during 2024, for which there were no comparable costs in the same period of 2023 and an adjustment to bring the corporate bonus accrual down recorded in the three months ended June 30, 2023, for which there were no comparable adjustment in the same period of 2024.

R&D expense also includes payments made to expand our proteins product offering through our agreement with Navigo Proteins GmbH (“Navigo”). Such expenses were $0.9 million and $1.7 million for the three and six months ended June 30, 2024, as compared to $1.2 million and $2.3 million, respectively, for the same periods in 2023, in the form of milestone payments to Navigo.

Selling, general and administrative expenses (As Restated)

Selling, general and administrative (“SG&A”) expenses include the costs associated with selling our commercial products and costs required to support our marketing efforts, including legal, accounting, patent, shareholder services, amortization of intangible assets and other administrative functions.

SG&A costs increased by $16.4 million, or 33.4% during the three months ended June 30, 2024 and increased $21.9 million, or 20.8% during the six months ended June 30, 2024, as compared to the same periods of 2023. The increase in SG&A costs partially relate to the results of operations of FlexBiosys and Metenova, which have been included in our consolidated results of operations since the acquisition dates in April 2023 and October 2023, respectively. SG&A expenses also increased during the three and six months ended June 30, 2024, as compared to the same period of 2023 due to increases in employee-related costs, stock-based compensation, professional services and amortization. In addition, there were $0.2 million and $0.9 million in costs incurred from restructuring activities during the three and six months ended June 30, 2024, respectively, for which there were no

36

comparable costs in the same periods of 2023. The increase in employee-related costs during the three and six months ended June 30, 2024, as compared to the same period of 2023 was due to an increase in SG&A headcount since June 30, 2023. Also included in this increase was the impact of an adjustment recorded during the second quarter of 2023 to decrease the bonus accrual, resulting in an increase to the expense for the three and six months ended June 30, 2024, as compared to the same period of 2023. In addition, the increase in employee-related costs for the six month period was also a result of our annual merit increase in salaries which occurred in the first quarter of 2024. During the second quarter of 2024, we recorded the incremental stock compensation expense of $5.0 million associated with the modification of our Chief Executive Officer’s (“CEO”) unvested equity awards resulting from the announcement of his transition from CEO to Executive Chair of our Board, which was announced on June 12, 2024 and effective September 1, 2024. For more information on the CEO’s transition to Executive Chair of our Board. See Note 10, ”Stockholders’ Equity - Chief Executive Officer Accounting Modifications” included in this report. Professional fees increased primarily due to added legal services during the second quarter of 2024.

Contingent consideration

Contingent consideration expense represents the change in fair value of the contingent consideration obligation included in current and noncurrent contingent consideration on the condensed consolidated balance sheets as of the end of each period. Remeasurement of the contingent consideration obligation is done each quarter and the carrying value of the obligation is adjusted to the current fair value through our condensed consolidated statements of comprehensive income (loss). Expected results and a change in market inputs used to calculate the discount rate, resulted in a change reported for the three and six months ended June 30, 2023 of $1.8 million and $3.0 million, respectively. No adjustment was recorded for the three and six months ended June 30, 2024 as management’s assessment was that the balances of the contingent consideration obligations already represented fair value.

Other income, net

The table below provides detail regarding our other income, net:

|  | Three Months Ended June 30, |  |  | Increase/(Decrease) |  |  | Six Months Ended June 30, |  |  | Increase/(Decrease) |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |  |  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
|  | (Amounts in thousands, except for percentage data) |
|  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |  |  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |
Investment income |  | $ | 9,411 |  |  | $ | 5,964 |  |  | $ | 3,447 |  |  |  | 57.8 | % |  | $ | 18,404 |  |  | $ | 11,450 |  |  | $ | 6,954 |  |  |  | 60.7 | %
Interest expense |  |  | (5,118 | ) |  |  | (411 | ) |  |  | (4,707 | ) |  |  | 1145.3 | % |  |  | (10,147 | ) |  |  | (819 | ) |  |  | (9,328 | ) |  |  | 1138.9 | %
Amortization of debt issuance costs |  |  | (520 | ) |  |  | (457 | ) |  |  | (63 | ) |  |  | 13.8 | % |  |  | (1,003 | ) |  |  | (914 | ) |  |  | (89 | ) |  |  | 9.7 | %
Other (expenses) income |  |  | (215 | ) |  |  | 528 |  |  |  | (743 | ) |  |  | (140.7 | %) |  |  | (3,751 | ) |  |  | 605 |  |  |  | (4,356 | ) |  |  | (720.0 | %)
Total other income, net |  | $ | 3,558 |  |  | $ | 5,624 |  |  | $ | (2,066 | ) |  |  | (36.7 | %) |  | $ | 3,503 |  |  | $ | 10,322 |  |  | $ | (6,819 | ) |  |  | (66.1 | %)

Investment income

Investment income includes income earned on invested cash balances. Our investment income increased by $3.4 million and $7.0 million for the three and six months ended June 30, 2024, as compared to the same periods of 2023 due to an increase in interest rates on higher average invested cash balances since June 30, 2023. Offsetting this increase was a decrease in interest earned in 2023 on U.S. treasury bills purchased at the end of 2022, for which there was no comparable amount recorded in 2024. We expect investment income to vary based on changes in the amount of funds invested and fluctuation of interest rates.

Interest expense

Interest expense for the three and six months ended June 30, 2024 is primarily from contractual coupon interest on the convertible debt outstanding as of June 30, 2024. On December 14, 2023, we entered into a privately negotiated exchange and subscription agreement with certain holders of our 0.375% Convertible Senior Notes due 2024 (the “2019 Notes”) and certain new investors pursuant to which we issued $600.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “2023 Notes”). Interest expense for the three and six months ended June 30, 2024 was $0.1 million of interest on the 2019 Notes for each period, compared to $0.3 million and $0.5 million, respectively of interest expense on the 2019 Notes in the same periods of 2023. Interest expense for the three and six months ended June 30, 2024 also includes $1.5 million and $3.0 million, respectively, of contractual coupon interest on the 2023 Notes as well as $3.4 million and $6.7 million, respectively, in accretion of the $82.1 million debt discount on the modified notes, which includes the accretion of an increase in principal and the accretion of increased

37

fair value of the conversion option for the three and six months ended June 30, 2024, for which there were no comparable costs in the same periods of 2023. See Note 9, “Convertible Senior Notes,” to our condensed consolidated financial statements included in this report for more information on this transaction.

Amortization of debt issuance costs

Transaction costs related to the issuance of the 2019 Notes and the 2023 Notes are amortized to amortization of debt issuance costs on the condensed consolidated statements of comprehensive income (loss). For the three and six months ended June 30, 2024, amortization of debt issuance costs included $0.1 million and $0.2 million, respectively, of amortization of costs related to the 2019 Notes and $0.4 million and $0.8 million, respectively, of amortization of costs related to the 2023 Notes, compared to $0.5 million and $0.9 million, respectively, of amortization related to the 2019 Notes recorded in the three and six months ended June 30, 2023.

Other (expenses) income

The change in other (expenses) income for the three and six months ended June 30, 2024, compared to the same periods of 2023, is primarily attributable to realized and unrealized foreign currency gains and losses related to transactions with customers and vendors, as well as the revaluation impact of intercompany loans with subsidiaries.

Income tax provision (As Restated)

Income tax provision for the three and six months ended June 30, 2024 and 2023 was as follows:

|  | Three Months Ended June 30, |  |  | Increase/(Decrease) |  |  | Six Months Ended June 30, |  |  | Increase/(Decrease) |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |  |  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
|  | (Amounts in thousands, except for percentage data) |
|  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |  |  | (As Restated) |  |  | (As Restated) |  |  |  |  |  |  |
Income tax provision |  | $ | 3,314 |  |  | $ | 5,119 |  |  | $ | (1,805 | ) |  |  | (35.3 | %) |  | $ | 3,713 |  |  | $ | 8,338 |  |  | $ | (4,625 | ) |  |  | (55.5 | %)
Effective tax rate |  |  | 36.7 | % |  |  | 20.6 | % |  |  |  |  |  |  |  |  | 29.2 | % |  |  | 19.2 | % |  |  |  |  |  |

For the three and six months ended June 30, 2024, we recorded an income tax provision of $3.3 million and $3.7 million, respectively. The effective tax rate was 36.7% and 29.2% for the three and six months ended June 30, 2024, respectively, and is based upon the estimated income for the year ending December 31, 2024 and the composition of income in different jurisdictions. The difference in effective tax rates between the periods was primarily due to lower income before income taxes and nondeductible stock compensation, partially offset by stock windfall tax benefits. Our effective tax rates for the three and six months ended June 30, 2024 were higher than the U.S. statutory rate of 21% primarily due to nondeductible stock compensation partially offset by stock windfall tax benefits.

For the three and six months ended June 30, 2023, we recorded an income tax provision of $5.1 million and $8.3 million, respectively. The effective tax rate was 20.6% and 19.2% for the three and six months ended June 30, 2023, respectively, and is based upon the estimated income for the year ending December 31, 2023 and the composition of income in different jurisdictions. The difference in effective tax rates between the periods was primarily due to lower income before income taxes and increased benefits from business tax credits partially offset by nondeductible contingent consideration and lower foreign-derived intangible income. Our effective tax rates for three and six months ended June 30, 2023 were lower than the U.S. statutory rate of 21% primarily due to business tax credits, foreign-derived intangible income and stock windfall tax benefits recognized on stock option exercises and the vesting of stock units.

In 2021, the Organization of Economic Co-operation and Development announced an Inclusive Framework on Base Erosion and Profit Sharing with the goal of achieving consensus around substantial changes to international tax policies, including the implementation of a minimum global effective tax rate of 15%. We continue to evaluate the impacts of enacted legislation and pending legislation in the tax jurisdictions in which we operate. While various countries have implemented the legislation as of January 1, 2024, we do not expect a resulting material impact to our income tax provision for the 2024 fiscal year.

38

Liquidity and Capital Resources (As Restated)

We have financed our operations primarily through revenues derived from product sales, the issuance of the 2019 Notes in July 2019, the 2023 Notes in December 2023 and the issuance of common stock in our December 2020, July 2019 and May 2019 public offerings. Our revenue for the foreseeable future will primarily be limited to our bioprocessing product revenue.

On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Subsequently, the U.S. Treasury, Federal Reserve and FDIC announced that SVB depositors would have access to all of their money. We have a banking relationship with SVB and hold cash, cash equivalents and marketable securities of $0.2 million as of June 30, 2024 in SVB depository accounts to cover short-term operational payments. While we have not experienced any losses in such accounts, the failure of SVB in 2023 caused us to utilize our accounts at other financial institutions in order to mitigate potential operational risks stemming from the temporary inability to access funds in our SVB operating accounts. As a result of bank failures, such as SVB, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired and could negatively impact the financial institutions with which we have direct arrangements, or the financial services industry or economy in general.

At June 30, 2024, we had cash and cash equivalents of $809.1 million compared to cash and cash equivalents of $751.3 million at December 31, 2023.

Working capital increased by $35.6 million to $982.0 million at June 30, 2024 from $946.4 million at December 31, 2023 due to the various changes noted below.

On December 14, 2023, the Company issued $600.0 million aggregate principal amount of its 2023 Notes in a private placement pursuant to separate, privately negotiated exchange and subscription agreements (the “Exchange and Subscription Agreements”) with a limited number of holders of its outstanding 2019 Notes and certain other qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (“Securities Act”). Pursuant to the Exchange and Subscription Agreements, the Company exchanged $217.7 million of its 2019 Notes for $309.9 million aggregate principal amount of the 2023 Notes (the “Exchange Transaction”) and issued $290.1 million aggregate principal amount of the 2023 Notes (the “Subscription Transactions”) for $290.1 million in cash. Proceeds from the Subscription Transactions amounted to $276.1 million after debt issuance costs of $13.9 million. The 2023 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 1.00% per year. Interest is payable semi-annually in arrears on each June 15 and December 15, commencing on June 15, 2024. The 2023 Notes will mature on December 15, 2028, unless earlier redeemed, repurchased or converted. During the first quarter of 2024, the closing price of the Company's common stock did not exceed 130% of the conversion price of the 2023 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. As a result, the 2023 Notes are not convertible at the option of the holders of the 2023 Notes during the third quarter of 2024, the quarter immediately following the quarter when the conditions are met, as stated in the indenture governing the 2023 Notes. For more information on the 2023 Notes, see Note 9, "Convertible Senior Notes," to this report.

The remaining 2019 Notes are convertible at the option of the holders as of June 30, 2024 at any time regardless of prior conditions that were in place and will be convertible until the close of business on July 11, 2024, the second trading day immediately preceding the maturity date of the 2019 Notes during the second quarter of 2024, the quarter immediately following the quarter when the conditions are met, as stated in the terms of the 2019 Notes. As of the date of this filing, excluding the Exchange Transaction mentioned above, the Company has received requests to convert $0.3 million aggregate principal amount of the 2019 Notes and all but $5,000 in aggregate principal requested prior to June 30, 2024 have been settled as of June 30, 2024. These conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. The remaining $5,000 in aggregate principal will settle with the 2019 Notes that are submitted for conversion prior to July 11, 2024. We will use proceeds from the Exchange Transaction to finance in part, the settlement upon conversion of the remaining 2019 Notes at maturity on July 15, 2024.

39

Cash Flows

|  | Six Months Ended June 30, |  |  | Increase/(Decrease) |
|  | 2024 |  |  | 2023 |  |  | $ Change |
|  | (Amounts in thousands) |
Cash provided by (used in): |  | (As Restated) |  |  | (As Restated) |  |  |  |
Operating activities |  | $ | 86,898 |  |  | $ | 45,622 |  |  | $ | 41,276 |
Investing activities |  |  | (15,762 | ) |  |  | 55,400 |  |  |  | (71,162 | )
Financing activities |  |  | (14,747 | ) |  |  | (18,388 | ) |  |  | 3,641 |
Effect of exchange rate changes on cash and cash equivalents |  |  | 1,434 |  |  |  | (2,436 | ) |  |  | 3,870 |
Net increase in cash and cash equivalents |  | $ | 57,823 |  |  | $ | 80,198 |  |  | $ | (22,375 | )

Operating activities (As Restated)

For the six months ended June 30, 2024, our operating activities provided cash of $86.9 million reflecting net income of $9.0 million and non-cash charges totaling $65.3 million primarily related to depreciation, intangible amortization, amortization of debt discount and issuance costs, stock-based compensation charges, deferred income taxes and operating lease right of use asset amortization. We had a decrease in inventory manufactured that provided $10.5 million, a net increase in accounts payable and accrued expenses of $3.8 million, primarily due to an increase in unearned revenue and accrued employee bonuses, and a net increase in operating lease liability due to new operating leases entered into during 2024 providing cash of $7.5 million. An decrease in prepaid expenses, primarily related to subscriptions and taxes consumed $0.5 million. The remaining cash used in operating activities resulted from unfavorable changes in various other working capital accounts.

For the six months ended June 30, 2023, our operating activities provided cash of $45.6 million reflecting net income of $35.1 million and non-cash charges totaling $51.4 million primarily related to depreciation, amortization, contingent consideration fair value adjustments, deferred income taxes, stock-based compensation charges and operating lease right of use asset amortization. An increase in accounts receivable consumed $4.6 million of cash and was primarily driven by the timing of collections from customers. Additionally, we had an increase in inventory manufactured that consumed $2.5 million and an $12.9 million increase in prepaid expenses, primarily related to prepaid taxes and subscriptions. A decrease in accounts payable consumed $3.9 million and was due to the timing of payments to vendors. A decrease in accrued liabilities consumed $11.8 million primarily related to the payment of employee bonuses during the six months ended June 30, 2023. The remaining cash provided by operating activities resulted from favorable changes in various other working capital accounts.

Investing activities

Our investing activities consumed $15.8 million of cash during the six months ended June 30, 2024, which was due to capital expenditures during 2024. Included in this amount were capitalized costs related to our internal-use software for the six months ended June 30, 2024.

Our investing activities provided $55.4 million of cash during the six months ended June 30, 2023, primarily due to the maturity of our short-term investment in U.S. treasury securities in June 2023, which provided cash of $102.3 million. We used $28.1 million in cash (net of cash received) for the FlexBiosys Acquisition. Capital expenditures consumed $18.8 million in 2023 as we continued to increase our manufacturing capacity worldwide. Of these expenditures, $2.1 million represented capitalized costs related to our internal-use software for the six months ended June 30, 2023.

Financing activities

Our financing activities consumed $14.7 million of cash for the six months ended June 30, 2024, primarily for $8.9 million in cash disbursed for shares withheld to cover employee income tax due upon the vesting and release of restricted stock units and the payments of $2.2 million and $5.2 million to settle the cash portion of the contingent earnout obligations related to our acquisition of FlexBiosys in April 2023 and Avitide in September 2021, respectively. These payments were partially offset by proceeds received from stock option exercises during the period.

Our financing activities consumed $18.4 million of cash during the six months ended June 30, 2023, primarily for $11.1 million of cash disbursed in relation to shares withheld to cover employee income tax due upon the vesting and release of restricted stock units and the payment of $7.3 million to settle the cash portion of the contingent earnout obligation related to our acquisition of Avitide. This was partially offset by proceeds received from stock option exercises during the period.

40

Effect of exchange rate changes on cash and cash equivalents

The effect of exchange rate changes on cash during the six months ended June 30, 2024 is a result of the weakening of the Swedish krona against the U.S. dollar by 5% and the weakening of the Euro against the U.S. dollar by 3%.

Our future capital requirements will depend on many factors, including the following:

•
the expansion of our bioprocessing business;
•
the ability to sustain sales and profits of our bioprocessing products and successfully integrate them into our business;
•
our ability to acquire additional bioprocessing products;
•
the scope of and progress made in our R&D activities;
•
the scope of investment in our intellectual property portfolio;
•
contingent consideration earnout payments resulting from our acquisitions;
•
the extent of any share repurchase activity;
•
the success of any proposed financing efforts;
•
general economic and capital markets;
•
change in accounting standards;
•
the impact of inflation on our operations, including our expenditures on raw materials and freight charges;
•
fluctuations in foreign currency exchange rates; and
•
costs associated with our ability to comply with, emerging environmental, social and governance standards.

Absent acquisitions of additional products, product candidates or intellectual property and absent the need to satisfy any debt conversions, we believe our current cash balances are adequate to meet our cash needs for at least the next 24 months from the date of this filing. We expect operating expenses for the remainder of the fiscal year to increase as we continue to expand our bioprocessing business. We expect to incur continued spending related to the development and expansion of our bioprocessing product lines and expansion of our commercial capabilities for the foreseeable future. Our future capital requirements may include, but are not limited to, purchases of property, plant and equipment, the acquisition of additional bioprocessing products and technologies to complement our existing manufacturing capabilities and continued investment in our intellectual property portfolio.

We plan to continue to invest in our bioprocessing business and in key R&D activities associated with the development of new bioprocessing products. We actively evaluate various strategic transactions on an ongoing basis, including acquiring products, technologies or businesses that would complement our existing portfolio. We continue to seek to acquire such potential assets that may offer us the best opportunity to create value for our shareholders. In order to acquire such assets, we may need to seek additional financing to fund these investments. If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of any such acquisition-related financing needs, the need to fund debt conversions, or due to lower demand for our products, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt funding. The sale of equity and convertible debt securities may result in dilution to our shareholders, and those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights. We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, if at all.

Net Operating Loss Carryforwards (As Restated)

At December 31, 2023, the Company had federal net operating loss carryforwards of $31.1 million, state net operating loss carryforwards of $4.8 million and foreign net operating loss carryforwards of $4.9 million. The state net operating loss carryforwards will expire at various dates through 2043, while the federal and foreign net operating loss carryforwards have unlimited carryforward periods and do not expire. We had federal and state business tax credits carryforwards of $5.8 million available to reduce future federal and state income taxes. The business tax credits carryforwards will expire at various dates through December 2043. Net operating loss carryforwards and available tax credits are subject to review and possible adjustment

41

by the Internal Revenue Service, state and foreign jurisdictions and may be limited in the event of certain changes in the ownership interest of significant shareholders.

Effects of Inflation

Our assets are primarily monetary, consisting mainly of cash and cash equivalents. Because of their liquidity, these assets are not directly affected by inflation. Since we intend to retain and continue to use our equipment, furniture, fixtures and office equipment, computer hardware and software and leasehold improvements, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources.

Cautionary Statement Regarding Forward-Looking Statements

This Amendment contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Amendment do not constitute guarantees of future performance. Investors are cautioned that statements in this Amendment which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, potential impairment of future earnings, management’s strategy, plans and objectives for future operations or acquisitions, expectations and beliefs for recently-completed acquisitions, product development and sales, restructuring activities and the expected results thereof, product candidate research, development and regulatory approval, SG&A expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans and the projected continued impact of, and response to, COVID-19 constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and management’s beliefs and assumptions. The Company undertakes no obligation to publicly update or revise the statements in light of future developments. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Company’s behalf. Words such as “expect,” “seek,” “anticipate,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the success of current and future collaborative or supply relationships, including our agreements with Cytiva, MilliporeSigma and Purolite Life Sciences, an Ecolab Inc. company; our ability to successfully grow our bioprocessing business, including as a result of acquisitions, commercialization or partnership opportunities, and our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all U.S. Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our patent and other intellectual property rights; the risk of litigation with collaborative partners; our manufacturing capabilities and our dependence on third-party manufacturers and value-added resellers; our ability to hire and retain skilled personnel; the market acceptance of our products, reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to integrate acquired businesses successfully into our business and achieve the expected benefits of the acquisitions; our ability to compete with larger, better financed life sciences companies; our history of losses and expectation of incurring losses; our ability to generate future revenues; our ability to successfully integrate our recently acquired businesses; our ability to raise additional capital to fund potential acquisitions; our volatile stock price; and the effects of our anti-takeover provisions. Further information on potential risk factors that could affect our financial results are included in the filings made by us from time to time with the SEC including under the sections entitled “Risk Factors” in our Form 10-K/A.

ITEM 4. CONTROLS AN D PROCEDURES

Disclosure Controls and Procedures

The Company’s management is responsible for establishing and maintaining adequate DCPs (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). DCPs are those controls and procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is

42

accumulated and communicated to the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation as of June 30, 2024 of the effectiveness of the design and operation of the Company’s DCPs pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based on such evaluation, the principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective because of the previously reported material weaknesses in our internal control over financial reporting, which are described in Part II, Item 9A, “Controls and Procedures” of our Annual Report on Form 10-K/A for the year ended December 31, 2023.

Material Weaknesses in Internal Control Over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. As of December 31, 2023, and as disclosed in the Company’s Form 10-K/A, the Company identified the following material weaknesses in internal control over financial reporting:

1.
A material weakness in the operation of our controls over the deferred income tax accounting for complex and non-routine transactions. Specifically, management did not have adequate supervision and review controls over the complex accounting for deferred income tax on the exchange of our outstanding 0.375% Convertible Senior Notes due 2024 and the issuance of 1.00% Convertible Senior Notes due 2028, including work performed by external advisors and the internal review of such transaction and related analyses.
2.
As a result of the restatement, a material weakness related to the design and operating effectiveness of controls related to revenue recognition specific to the evaluation of accounting for contract terms.

As of June 30, 2024, the Company has not remediated these material weaknesses. As a result, the Company’s management concluded that at June 30, 2024, the Company’s internal control over financial reporting was not effective.

Remediation Plan for Material Weaknesses

As previously disclosed in the Form 10-K/A, management is implementing remedial actions under the oversight of the Audit Committee of the Board of Directors to address the identified deficiencies.

Our income tax remediation efforts include the following activities:

•
Improve our process to identify and select qualified third-party advisors, including enhanced review of capabilities and work performed, specifically related to the review of tax advice and related accounting guidance.
•
Implement a process to verify the controls, processes and internal reviews performed by third-party advisors.
•
Consider whether the non-routine transaction warrants additional advisor oversight or validation of analyses based on complexity or changes in applicable regulations.
•
Increase education for internal resources on complex transactions to enhance diligence capabilities with third-party advisors.

Our revenue recognition remediation efforts include the following activities:

•
Designing new internal controls to validate there is a complete listing of revenue contracts that have non-standard terms, which require incremental accounting analysis under ASC 606.
•
Designing new internal controls evaluating the accounting for contract amendments, including amendments accounted for as contract modifications.
•
Enhancing and expanding our existing revenue recognition control procedures and attributes when evaluating the accounting impact of non-standard contract terms and contract modifications.
•
Increasing education for internal resources on accounting for contracts within the scope of ASC 606 and deploying enablers to facilitate documentation of accounting analyses and conclusions.

43

We will continue to monitor the design and operating effectiveness of these and other processes, procedures and controls and make any further changes management determines appropriate.

Changes in Internal Control

Except for the material weaknesses described above, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

44

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

The matters discussed in this Amendment include forward-looking statements that involve risks or uncertainties. These statements are neither promises nor guarantees, but are based on various assumptions by management regarding future circumstances, over many of which Repligen has little or no control. A number of important risks and uncertainties, including those identified under the caption “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K/A for the period ended December 31, 2023 (“Form 10-K/A”) and in subsequent filings, could cause our actual results to differ materially from those in the forward-looking statements.

As contemplated in Item 1A, entitled “Risk Factors,” in the Company's Form 10-K/A, the Company has in the past and may in the future experience data security incidents. If successful, these attacks could affect service reliability and threaten the confidentiality, integrity, and availability of information. The Company is updating the risk factor captioned ”Our internal computer systems, or those of our customers, collaborators or other contractors, may be subject to cyber-attacks or security breaches, which could result in a material disruption of our product development programs” to reference the following incident:

As described on the Current Report on Form 8-K filed on July 15, 2024, on July 9, 2024, the Company discovered that an unauthorized third party had accessed certain files on the Company’s information systems. Based on information currently known as of the date of this Amendment and management’s current assessment of quantitative and qualitative factors (including reputational harm, adverse impacts on relationships with vendors, customers and other business partners, and the impact of the foregoing on the Company’s stockholders), the Company does not believe this incident will have a material impact on its financial condition and results of operations. In addition, as of the date this Amendment other than the Company’s response and remediation activities, the incident has not had an impact on the Company’s business or operations.

Other than the foregoing, there have been no material changes to the risk factors disclosed in Item 1A, entitled “Risk Factors,” in the Company’s Form 10-K/A.

45

ITEM 6. EXHI BITS

Exhibit Number |  | Document Description
3.1 |  | Restated Certificate of Incorporation dated June 30, 1992, as amended September 17, 1999 (filed as Exhibit 3.1 to Repligen Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 1999 and incorporated herein by reference).
3.2 |  | Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation, effective as of May 16, 2014 (filed as Exhibit 3.1 to Repligen Corporation's Current Report on Form 8-K filed on May 19, 2014 and incorporated herein by reference).
3.3 |  | Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation, effective May 19, 2023 (filed as Exhibit 3.1 to Repligen Corporation's Current Report on Form 8-K filed on May 22, 2023 and incorporated herein by reference).
3.4 |  | Third Amended and Restated Bylaws (filed as Exhibit 3.1 to Repligen Corporation's Current Report on Form 8-K filed on January 28, 2021 and incorporated herein by reference).
10.1† |  | Fourth Amended and Restated Employment Agreement, dated June 12, 2024, by and between Repligen Corporation and Tony J. Hunt (filed with the Original Report).
10.2† |  | Employment Agreement, dated June 12, 2024, by and between Repligen Corporation and Olivier Loeillot (filed with the Original Report).
31.1 + |  | Rule 13a-14(a)/15d-14(a) Certification.
31.2 + |  | Rule 13a-14(a)/15d-14(a) Certification.
32.1 * |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH |  | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.
104 |  | Cover page formatted as Inline XBRL and contained in Exhibits 101.

+ Filed herewith.

* Furnished herewith.

† Indicates a management contract or a compensatory plan, contract or arrangement.

46

SIGNAT URES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | REPLIGEN CORPORATION
Date: November 18, 2024 |  | By: | /S/ O LIVIER L OEILLOT
|  |  | Olivier Loeillot
|  |  | Chief Executive Officer
|  |  | (Principal executive officer)
|  |  | Repligen Corporation
Date: November 18, 2024 |  | By: | /S/ J ASON K. G ARLAND
|  |  | Jason K. Garland
|  |  | Chief Financial Officer
|  |  | (Principal financial officer)
|  |  | Repligen Corporation

47